<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Drug interventions for the treatment of obesity in children and adolescents - Axon, E - 2016 | Cochrane Library</title> <meta content="Drug interventions for the treatment of obesity in children and adolescents - Axon, E - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012436/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Drug interventions for the treatment of obesity in children and adolescents - Axon, E - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012436/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012436" name="dc.identifier" scheme="DOI"/> <meta content="Drug interventions for the treatment of obesity in children and adolescents" name="citation_title"/> <meta content="Emma Axon" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="emma.axon@nottingham.ac.uk" name="citation_author_email"/> <meta content="Greg Atkinson" name="citation_author"/> <meta content="Teesside University" name="citation_author_institution"/> <meta content="Bernd Richter" name="citation_author"/> <meta content="Institute of General Practice, Medical Faculty of the Heinrich‐Heine‐University Düsseldorf" name="citation_author_institution"/> <meta content="Maria‐Inti Metzendorf" name="citation_author"/> <meta content="Institute of General Practice, Medical Faculty of the Heinrich‐Heine‐University Düsseldorf" name="citation_author_institution"/> <meta content="Louise Baur" name="citation_author"/> <meta content="The University of Sydney" name="citation_author_institution"/> <meta content="Nicholas Finer&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Eva Corpeleijn" name="citation_author"/> <meta content="University Medical Centre Groningen" name="citation_author_institution"/> <meta content="Claire O'Malley" name="citation_author"/> <meta content="Durham University" name="citation_author_institution"/> <meta content="Louisa J Ells" name="citation_author"/> <meta content="Teesside University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD012436" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/11/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012436/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012436/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012436/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti‐Obesity Agents [adverse effects, *therapeutic use]; Body Mass Index; Cyclobutanes [therapeutic use]; Fluoxetine [therapeutic use]; Lactones [therapeutic use]; Metformin [therapeutic use]; Orlistat; Pediatric Obesity [*drug therapy]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012436&amp;doi=10.1002/14651858.CD012436&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012436&amp;doi=10.1002/14651858.CD012436&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012436&amp;doi=10.1002/14651858.CD012436&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012436&amp;doi=10.1002/14651858.CD012436&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012436&amp;doi=10.1002/14651858.CD012436&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012436&amp;doi=10.1002/14651858.CD012436&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012436&amp;doi=10.1002/14651858.CD012436&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012436&amp;doi=10.1002/14651858.CD012436&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012436&amp;doi=10.1002/14651858.CD012436&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012436&amp;doi=10.1002/14651858.CD012436&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012436&amp;doi=10.1002/14651858.CD012436&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012436&amp;doi=10.1002/14651858.CD012436&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012436&amp;doi=10.1002/14651858.CD012436&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012436&amp;doi=10.1002/14651858.CD012436&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012436&amp;doi=10.1002/14651858.CD012436&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012436&amp;doi=10.1002/14651858.CD012436&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012436&amp;doi=10.1002/14651858.CD012436&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012436&amp;doi=10.1002/14651858.CD012436&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012436&amp;doi=10.1002/14651858.CD012436&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012436&amp;doi=10.1002/14651858.CD012436&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012436&amp;doi=10.1002/14651858.CD012436&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012436&amp;doi=10.1002/14651858.CD012436&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012436&amp;doi=10.1002/14651858.CD012436&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="XHP2gG4h";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012436\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012436\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012436\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012436\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ru","hr","pl","fr","ta","zh_HANS","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012436",title:"Drug interventions for the treatment of obesity in children and adolescents",firstPublishedDate:"Nov 29, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Metabolic and Endocrine Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XHP2gG4h&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012436&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012436';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012436/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012436/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012436%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012436/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012436/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012436/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012436/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012436" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;ta&quot;,&quot;title&quot;:&quot;எளியமொழிச் சுருக்கம்&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012436/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012436" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012436/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012436/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>13365 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012436" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012436/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012436/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012436/full#CD012436-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012436/full#CD012436-sec-0119"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012436/full#CD012436-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012436/full#CD012436-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012436/full#CD012436-sec-0043"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012436/full#CD012436-sec-0044"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012436/full#CD012436-sec-0074"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012436/full#CD012436-sec-0113"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012436/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012436/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012436/appendices#CD012436-sec-0124"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012436/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012436/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/table_n/CD012436StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/table_n/CD012436StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012436/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012436/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012436/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012436/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012436/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012436/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012436/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Drug interventions for the treatment of obesity in children and adolescents</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012436/information#CD012436-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Emma Axon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012436/information#CD012436-cr-0003">Greg Atkinson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012436/information#CD012436-cr-0004">Bernd Richter</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012436/information#CD012436-cr-0005">Maria‐Inti Metzendorf</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012436/information#CD012436-cr-0006">Louise Baur</a></li> <li class="author custom-tooltip" title="Please see Authors’ Declarations of Interest for further details."><a href="/cdsr/doi/10.1002/14651858.CD012436/information#CD012436-cr-0007">Nicholas Finer</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012436/information#CD012436-cr-0008">Eva Corpeleijn</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012436/information#CD012436-cr-0009">Claire O'Malley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012436/information#CD012436-cr-0010">Louisa J Ells</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012436/information/en#CD012436-sec-0142">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 November 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012436/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012436">https://doi.org/10.1002/14651858.CD012436</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012436-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012436-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012436-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012436-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012436-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012436-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012436-abs-0001" lang="en"> <section id="CD012436-sec-0001"> <h3 class="title" id="CD012436-sec-0001">Background</h3> <p>Child and adolescent obesity has increased globally, and can be associated with significant short‐ and long‐term health consequences. </p> </section> <section id="CD012436-sec-0002"> <h3 class="title" id="CD012436-sec-0002">Objectives</h3> <p>To assess the efficacy of drug interventions for the treatment of obesity in children and adolescents. </p> </section> <section id="CD012436-sec-0003"> <h3 class="title" id="CD012436-sec-0003">Search methods</h3> <p>We searched CENTRAL<i>,</i> MEDLINE, Embase, PubMed (subsets not available on Ovid), LILACS as well as the trial registers ICTRP (WHO) and ClinicalTrials.gov. Searches were undertaken from inception to March 2016. We checked references and applied no language restrictions. </p> </section> <section id="CD012436-sec-0004"> <h3 class="title" id="CD012436-sec-0004">Selection criteria</h3> <p>We selected randomised controlled trials (RCTs) of pharmacological interventions for treating obesity (licensed and unlicensed for this indication) in children and adolescents (mean age under 18 years) with or without support of family members, with a minimum of three months' pharmacological intervention and six months' follow‐up from baseline. We excluded interventions that specifically dealt with the treatment of eating disorders or type 2 diabetes, or included participants with a secondary or syndromic cause of obesity. In addition, we excluded trials which included growth hormone therapies and pregnant participants. </p> </section> <section id="CD012436-sec-0005"> <h3 class="title" id="CD012436-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trial quality and extracted data following standard Cochrane methodology. Where necessary we contacted authors for additional information. </p> </section> <section id="CD012436-sec-0006"> <h3 class="title" id="CD012436-sec-0006">Main results</h3> <p>We included 21 trials and identified eight ongoing trials. The included trials evaluated metformin (11 trials), sibutramine (six trials), orlistat (four trials), and one trial arm investigated the combination of metformin and fluoxetine. The ongoing trials evaluated metformin (four trials), topiramate (two trials) and exenatide (two trials). A total of 2484 people participated in the included trials, 1478 participants were randomised to drug intervention and 904 to comparator groups (91 participants took part in two cross‐over trials; 11 participants not specified). Eighteen trials used a placebo in the comparator group. Two trials had a cross‐over design while the remaining 19 trials were parallel RCTs. The length of the intervention period ranged from 12 weeks to 48 weeks, and the length of follow‐up from baseline ranged from six months to 100 weeks. </p> <p>Trials generally had a low risk of bias for random sequence generation, allocation concealment and blinding (participants, personnel and assessors) for subjective and objective outcomes. We judged approximately half of the trials as having a high risk of bias in one or more domain such as selective reporting. </p> <p>The primary outcomes of this review were change in body mass index (BMI), change in weight and adverse events. All 21 trials measured these outcomes. The secondary outcomes were health‐related quality of life (only one trial reported results showing no marked differences; very low certainty evidence), body fat distribution (measured in 18 trials), behaviour change (measured in six trials), participants' views of the intervention (not reported), morbidity associated with the intervention (measured in one orlistat trial only reporting more new gallstones following the intervention; very low certainty evidence), all‐cause mortality (one suicide in the orlistat intervention group; low certainty evidence) and socioeconomic effects (not reported). </p> <p>Intervention versus comparator for mean difference (MD) in BMI change was ‐1.3 kg/m<sup>2</sup> (95% confidence interval (CI) ‐1.9 to ‐0.8; P &lt; 0.00001; 16 trials; 1884 participants; low certainty evidence). When split by drug type, sibutramine, metformin and orlistat all showed reductions in BMI in favour of the intervention. </p> <p>Intervention versus comparator for change in weight showed a MD of ‐3.9 kg (95% CI ‐5.9 to ‐1.9; P &lt; 0.00001; 11 trials; 1180 participants; low certainty evidence). As with BMI, when the trials were split by drug type, sibutramine, metformin and orlistat all showed reductions in weight in favour of the intervention. </p> <p>Five trials reported serious adverse events: 24/878 (2.7%) participants in the intervention groups versus 8/469 (1.7%) participants in the comparator groups (risk ratio (RR) 1.43, 95% CI 0.63 to 3.25; 1347 participants; low certainty evidence). A total 52/1043 (5.0%) participants in the intervention groups versus 17/621 (2.7%) in the comparator groups discontinued the trial because of adverse events (RR 1.45, 95% CI 0.83 to 2.52; 10 trials; 1664 participants; low certainty evidence). The most common adverse events in orlistat and metformin trials were gastrointestinal (such as diarrhoea, mild abdominal pain or discomfort, fatty stools). The most frequent adverse events in sibutramine trials included tachycardia, constipation and hypertension. The single fluoxetine trial reported dry mouth and loose stools. No trial investigated drug treatment for overweight children. </p> </section> <section id="CD012436-sec-0007"> <h3 class="title" id="CD012436-sec-0007">Authors' conclusions</h3> <p>This systematic review is part of a series of associated Cochrane reviews on interventions for obese children and adolescents and has shown that pharmacological interventions (metformin, sibutramine, orlistat and fluoxetine) may have small effects in reduction in BMI and bodyweight in obese children and adolescents. However, many of these drugs are not licensed for the treatment of obesity in children and adolescents, or have been withdrawn. Trials were generally of low quality with many having a short or no post‐intervention follow‐up period and high dropout rates (overall dropout of 25%). Future research should focus on conducting trials with sufficient power and long‐term follow‐up, to ensure the long‐term effects of any pharmacological intervention are comprehensively assessed. Adverse events should be reported in a more standardised manner specifying amongst other things the number of participants experiencing at least one adverse event. The requirement of regulatory authorities (US Food and Drug Administration and European Medicines Agency) for trials of all new medications to be used in children and adolescents should drive an increase in the number of high quality trials. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012436-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012436-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012436-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012436-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012436-abs-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012436-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012436-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012436-abs-0017">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012436-abs-0009">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012436-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/ta#CD012436-abs-0011">தமிழ்</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012436-abs-0014">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012436-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012436-abs-0004" lang="en"> <h3>Drug interventions for the treatment of obesity in children and adolescents</h3> <p><b>Review question</b> </p> <p>Do drug (medicine) interventions reduce weight in obese children and adolescents and are they safe? </p> <p><b>Background</b> </p> <p>Across the world more children and adolescents are becoming overweight and obese. These children and adolescents are more likely to have health problems, both while as children or adolescents and in later life. More information is needed about what works best for treating this problem recognising that so‐called lifestyle changes (diet, exercise and counselling) have limited efficacy. </p> <p><b>Study characteristics</b> </p> <p>We found 21 randomised controlled studies (clinical studies where people are randomly put into one of two or more treatment groups) comparing various drugs plus a behaviour changing intervention such as diet, exercise or both (= intervention groups) usually with placebo (a pretend drug) plus a behaviour changing intervention (= control groups). We also identified eight ongoing studies (studies which are currently running but not completed yet). A total of 2484 children and adolescents took part in the included studies. The length of the intervention period ranged from 12 weeks to 48 weeks, and the length of follow‐up ranged from six months to 100 weeks. </p> <p><b>Key results</b> </p> <p>The included studies investigated metformin (10 studies), sibutramine (six studies), orlistat (four studies) and one study group evaluated the combination of metformin and fluoxetine. The ongoing studies are investigating metformin (four studies), topiramate (two studies) and exenatide (two studies). </p> <p>Most studies reported on body mass index (BMI) and bodyweight: BMI is a measure of body fat and is calculated from weight and height measurements (kg/m<sup>2</sup>). In children, BMI is often measured in a way that takes into account sex, weight and height as children grow older (BMI z score). The average change in BMI across control groups was between a 1.8 kg/m<sup>2</sup> reduction to a 0.9 kg/m<sup>2</sup> increase, while across all intervention groups the average reduction was more pronounced (1.3 kg/m<sup>2</sup> reduction). The same effect was observed for weight change: on average, children and adolescents in the intervention groups lost 3.9 kg more weight than the children and adolescents in the control groups. Study authors reported an average of serious side effects in 24 per 1000 participants in the intervention groups compared with an average of 17 per 1000 participants in the control groups. The numbers of participants dropping out of the study because of side effects were 40 per 1000 in the intervention groups and 27 per 1000 in the control groups. The most common side effects in the orlistat and metformin studies were gut (such as diarrhoea and mild tummy pain). Common side effects in the sibutramine trials included increased heart rate (tachycardia), constipation and high blood pressure. The fluoxetine study reported dry mouth and loose stools. One study reported health‐related quality of life (a measure of physical, mental, emotional and social functioning) and found no marked differences between intervention and control. No study reported the participants' views of the intervention or socioeconomic effects. Only one study reported on morbidity (how often a disease occurs in a specific area) associated with the intervention, where there were more gallstones after the orlistat treatment. Study authors reported one suicide in the orlistat intervention group. However, studies were not long enough to reliably investigate death from any cause. No study investigated drug treatment for children who were only overweight (obese children have a much higher weight, BMI or BMI z score than children being overweight). </p> <p>This evidence is up to date to March 2016.</p> <p><b>Quality of the evidence</b> </p> <p>The overall certainty of the evidence was low or very low, mainly because there were only a few studies per outcome measurement, the number of included children or adolescents was small, and due to variation in the results of the studies. In addition, many children or adolescents left the studies before the study had finished. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012436-sec-0119" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012436-sec-0119">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012436-sec-0179">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012436-sec-0119"></div> <h3 class="title" id="CD012436-sec-0120">Implications for practice</h3> <section id="CD012436-sec-0120"> <p>This systematic review highlights the paucity of both the availability of reliable pharmacotherapy options for the treatment of obese children and adolescents, and the clinical trial evidence to support efficacy and safety. Trial quality and reporting overall was poor, with high dropout and discontinuation rates. Many of the trials assessed the efficacy of drugs which have now been withdrawn (sibutramine) or are not recommended for obesity treatment (metformin) in many countries. </p> <p>In this review, we found an overall reduction in body mass index (BMI) of 1.3 kg/m<sup>2</sup> in favour of the drug interventions. Using the International Obesity Task Force (IOTF) BMI cut‐offs for overweight and obesity (<a href="./references#CD012436-bbs2-0188" title="ColeTJ , LobsteinT . Extended international (IOTF) body mass index cut offs for thinness, overweight and obesity. Pediatric Obesity2012;7:284‐94. ">Cole 2012</a>), a 12‐year‐old boy would have a cut‐off of 21.2 kg/m<sup>2</sup> for being overweight, 26.02 kg/m<sup>2</sup> for being obese and 31.21 kg/m<sup>2</sup> for being morbidly obesity. Therefore, it would be possible for a 12‐year‐old boy who reduces his BMI by 1.3 kg/m<sup>2</sup> to move down a weight status category ‐ but only if they happen to lie just above the cut‐off points. This is also similar for girls and older children. In terms of a standardised mean difference (SMD), the reduction in BMI found in this review would equate to a reduction of 0.28 between‐individuals standard deviation scores. </p> <p>Whilst this finding suggests that drug interventions can result in a small BMI and weight reduction over the short term, it is not known whether this is: </p> <p> <ul id="CD012436-list-0015"> <li> <p>sustainable over the longer term, which is an important consideration given evidence from the pharmacological management of adult obesity demonstrating a need for continued medication to maintain weight loss (<a href="./references#CD012436-bbs2-0277" title="YanovskiSZ , YanovskiJA . Long‐term drug treatment of obesity: a systematic and clinical review. JAMA2014;311(1):74‐86. [DOI: 10.1001/jama.2013.281361] ">Yanovski 2014</a>), that is, drug withdrawal is followed by weight regain, which occurred in <a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a>, <a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a>, and <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a> during the drug‐free follow‐up. </p> </li> <li> <p>has any impact on existing or future clinical risk factors or disease. Additionally, though all trials reported adverse events, quantitative data were only available in the minority of the included trials. This is particularly important as none of the included trials collected data on participants' views. </p> </li> </ul> </p> </section> <h3 class="title" id="CD012436-sec-0121">Implications for research</h3> <section id="CD012436-sec-0121"> <p>As new pharmacotherapies for the treatment of adult obesity become available (phentermine plus topiramate extended release; liraglutide 3.0 mg; bupropion plus naltrexone; lorcaserin), there may be a demand for an evaluation of their efficacy within an obese paediatric population. The requirement of regulatory authorities (US Food and Drug Administration (FDA) and European Medicines Agency (EMA)) for trials of all new medications to be used in children and adolescents should drive more and better trials. Hence, any future trials should ensure they are evaluated over the longer term (i.e. longer than one year) and collect data on cardiovascular and metabolic parameters, morbidities, health‐related quality of life, social and psychological well‐being, diet and physical activity behaviours, participant views and socioeconomic effects. It is also important that new trials' protocols reduce all possible sources of bias and provide accurate interpretation of findings, by ensuring power calculations and intention‐to‐treat analyses are described and conducted, and robust sequence allocation, allocation concealment methods and blinding measures are used and comprehensively described. All new trial protocols should also be registered and published to ensure reporting bias can be assessed. There should also be standardisation in reporting to ensure all trials report a raw BMI score and adverse events per participant. As evidence from adult weight management indicates the intensity of adjunctive lifestyle interventions can impact on weight loss and associated outcomes, future trials should aim to ensure they maximise and adequately report any concomitant behaviour changing programme. Participant retention is also an issue that needs addressing with improved and novel mechanisms to reduce dropout rates and ensure treatment concordance. Since overweight and obesity is developing at an increasingly early age, future evaluation and trials may need to consider recruiting young, prepubertal participants in whom clearly high levels of safety will need to be established. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012436-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012436-sec-0036"></div> <div class="table" id="CD012436-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Drug interventions for the treatment of obesity in children and adolescents</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Drug interventions for the treatment of obesity in children and adolescents</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> obese children and adolescents </p> <p><b>Settings:</b> mainly outpatient settings </p> <p><b>Intervention:</b> metformin, orlistat, sibutramine usually combined with behaviour changing interventions </p> <p><b>Comparison:</b> placebo or no placebo usually with behaviour changing interventions </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Pharmacological intervention</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>a. BMI (</b>kg/m<sup>2</sup>)<br/> Follow‐up: 6 months (14 trials) ‐ 12 months (2 trials) </p> <p><b>b. Body weight (kg)</b> </p> <p>Follow‐up: 6 months (10 trials) ‐ 12 months (1 trial)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>a. The mean reduction in BMI ranged across control groups from ‐1.8 to +0.9</p> <p>b. The mean reduction in weight ranged across control groups from ‐3.8 kg to +4.9 kg </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>a. The mean reduction in BMI in the intervention groups was ‐<b>1.3 higher</b> (‐1.9 to ‐0.8 higher) </p> <p>b. The mean reduction in weight in the intervention groups was <b>‐3.9 kg higher</b> (‐5.9 kg to ‐1.9 kg higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 1884 (16)</p> <p>b. 1180 (11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a.</p> <p>⊕⊕⊝⊝<br/> <b>L ow<sup>a</sup> </b> </p> <p>b.</p> <p>⊕⊕⊝⊝<br/> <b>Low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>a. Serious adverse events</p> <p>b. Discontinuation of trial because of adverse events</p> <p>Follow‐up: mostly 6 months, maximum 100 weeks (1 trial)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>a. <b>17 per 1000</b> </p> <p>b. <b>27 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>a. <b>24 per 1000</b> (11 to 55) </p> <p>b. <b>40 per 1000</b> (23 to 69) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a.<b>RR 1.43</b> (0.63 to 3.25) </p> <p>b.<b>RR 1.45</b> (0.83 to 2.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 1347 (5)</p> <p>b. 1664 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a.</p> <p>⊕⊕⊕⊝</p> <p><b>L ow<sup>b</sup> </b> </p> <p>b.</p> <p>⊕⊕⊕⊝</p> <p><b>Low<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All trials reported if adverse events occurred; however, only 7/20 trials reported the number of participants who experienced at least 1 adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> <p>3 questionnaires (1 trial) and SF‐36 (1 trial)</p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>V ery low<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results were only reported for SF‐36 (1 trial on sibutramine, 46 children), there were no marked differences between intervention and comparator groups </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: mostly 6 months, maximum 100 weeks (1 trial)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2176 (20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>L ow<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 suicide in the orlistat intervention group</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Morbidity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>533 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>V ery low<sup>e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 1 trial investigated morbidity defined as illness or harm associated with the intervention (<a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>). In the orlistat group 6/352 (1.7%) participants developed new gallstones compared with 1/181 (0.6%) in the placebo group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Socioeconomic effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>BMI:</b> body mass index; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SF‐36:</b> Short‐Form Health Survey 36 items. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*Assumed risk was derived from the event rates in the comparator groups.</p> <p><sup>a</sup>Downgraded by two levels because of potential other risk of bias, inconsistency and imprecision (see <a href="./appendices#CD012436-sec-0137">Appendix 13</a>).<br/> <sup>b</sup>Downgraded by two levels because of potential reporting bias, inconsistency and imprecision (see <a href="./appendices#CD012436-sec-0137">Appendix 13</a>).<br/> <sup>c</sup>Downgraded by three levels because of one trial only with a small number of participants and imprecision (see <a href="./appendices#CD012436-sec-0137">Appendix 13</a>).<br/> <sup>d</sup>Downgraded by two levels because of short follow‐up periods and no trial was powered to investigate mortality (see <a href="./appendices#CD012436-sec-0137">Appendix 13</a>).<br/> <sup>e</sup>Downgraded by three levels because of one trial only and imprecision (see <a href="./appendices#CD012436-sec-0137">Appendix 13</a>). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012436-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012436-sec-0037">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012436-sec-0153">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD012436-sec-0037"></div> <p>The prevalence of overweight and obese children and adolescents has increased throughout the world, presenting a global public health crisis (<a href="./references#CD012436-bbs2-0237" title="NgM , FlemingT , RobinsonM , ThomsonB , GraetzN , MargonoC , et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980‐2013: a systematic analysis of the Global Burden of Disease Study 2013. Lancet2014;384(9945):766‐81. ">Ng 2014</a>; <a href="./references#CD012436-bbs2-0272" title="World Health Organization. Fact sheet on overweight and obesity. www.who.int/mediacentre/factsheets/fs311/en/ (accessed 24 February 2015). ">WHO 2015</a>). It is not only a problem in high‐income countries, but a high prevalence has also been found in low‐ and middle‐income countries (<a href="./references#CD012436-bbs2-0267" title="WangY , LimH . The global childhood obesity epidemic and the association between socio‐economic status and childhood obesity. International Review of Psychiatry2012;24(3):176‐88. ">Wang 2012</a>). Evidence suggests that rates are slowing down or plateauing in high‐income countries; however, they are still rising in low‐ or middle‐income countries and prevalence continues to remain high in both (<a href="./references#CD012436-bbs2-0239" title="OldsT , MaherC , ZuminS , PeneauS , LioretS , CastetbonK , et al. Evidence that the prevalence of childhood overweight is plateauing: data from nine countries. International Journal of Pediatric Obesity2011;6:342‐60. [DOI: 10.3109/17477166.2011.605895] ">Olds 2011</a>; <a href="./references#CD012436-bbs2-0254" title="RokholmB , BakerJL , SørensonTIA . The levelling off of the obesity epidemic since the year 1999 ‐ a review of evidence and perspectives. Obesity Reviews2010;11:835‐46. ">Rokholm 2010</a>). The Global Burden of Disease Study 2013 reported a mean of 24% of boys and 23% of girls from high‐income countries to be overweight or obese, whilst the estimated percentages of boys and girls in low‐ or middle‐income countries who are overweight or obese are 13% each (<a href="./references#CD012436-bbs2-0237" title="NgM , FlemingT , RobinsonM , ThomsonB , GraetzN , MargonoC , et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980‐2013: a systematic analysis of the Global Burden of Disease Study 2013. Lancet2014;384(9945):766‐81. ">Ng 2014</a>). This report used the International Obesity Task Force (IOTF) age and sex standardised cut points (<a href="./references#CD012436-bbs2-0186" title="ColeTJ , BellizziMC , FlegalKM , DietzWH . Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ2000;320:1240‐53. ">Cole 2000</a>). Furthermore, young children also have a high prevalence of being overweight or obese with an estimated 42 million overweight or obese children under five years of age in 2010 (approximately 35 million living in low‐ or middle‐income countries ‐ <a href="./references#CD012436-bbs2-0191" title="DeOnisM , Blossner M.Borghi , E . Global prevalence and trends of overweight and obesity among preschool children. American Journal of Clinical Nutrition2010;92:1257‐64. ">De Onis 2010</a>); these statistics were based on the World Health Organization (WHO) growth standard (<a href="./references#CD012436-bbs2-0271" title="World Health Organization. The WHO Child Growth Standards. www.who.int/childgrowth/standards/Technical_report.pdf 2006 (accessed 08/11/2016). ">WHO 2006</a>). </p> <p>An additional concern in some high‐income countries, such as the USA (<a href="./references#CD012436-bbs2-0219" title="KellyAS , BarlowSE , RaoG , IngeTH , HaymanLL , SteinbergerJ , et al. Severe obesity in children and adolescents: identification, associated health risks, and treatment approaches: a scientific statement From the American Heart Association. Circulation2013;128:1689‐712. ">Kelly 2013</a>; <a href="./references#CD012436-bbs2-0259" title="SkinnerAC , SkeltonJA . Prevalence and trends in obesity and severe obesity among children in the United States, 1999‐2012. JAMA Pediatrics2014;168(6):561‐6. [DOI: 10.1001/jamapediatrics.2014.21] ">Skinner 2014</a>) and England (<a href="./references#CD012436-bbs2-0184" title="Chief Medical Officer. Chief Medical Officer annual report: surveillance volume 2012. www.gov.uk/government/publications/chief‐medicalofficer‐annual‐report‐surveillance‐volume‐2012 27 March 2014. ">CMO 2014</a>; <a href="./references#CD012436-bbs2-0195" title="EllsL , HancockC , CopleyVR , MeadE , DinsdaleH , KinraS , et al. Prevalence of severe childhood obesity in England: 2006‐2013. Archives of Disease in Childhood2015;100(7):631‐6. [DOI: 10.1136/archdischild‐2014‐307036] ">Ells 2015a</a>), is the rise in severe paediatric obesity. In England during 2012/2013, 2.9% of girls and 3.9% of boys, aged 10 to 11 years, were classified as severely obese (body mass index (BMI) UK90 99.6th centile or greater ‐ <a href="./references#CD012436-bbs2-0195" title="EllsL , HancockC , CopleyVR , MeadE , DinsdaleH , KinraS , et al. Prevalence of severe childhood obesity in England: 2006‐2013. Archives of Disease in Childhood2015;100(7):631‐6. [DOI: 10.1136/archdischild‐2014‐307036] ">Ells 2015a</a>). In the USA from 2011 to 2012, 2.1% of youths (aged 2 to 19 years) were categorised as class 3 obese (Centers for Disease Control and Prevention growth charts: BMI  140% of greater of the 95th percentile or BMI  40 kg/m<sup>2</sup> or greater ‐ <a href="./references#CD012436-bbs2-0259" title="SkinnerAC , SkeltonJA . Prevalence and trends in obesity and severe obesity among children in the United States, 1999‐2012. JAMA Pediatrics2014;168(6):561‐6. [DOI: 10.1001/jamapediatrics.2014.21] ">Skinner 2014</a>). </p> <p>Whilst the IOTF published an international definition for paediatric severe (morbid) obesity in 2012 (<a href="./references#CD012436-bbs2-0188" title="ColeTJ , LobsteinT . Extended international (IOTF) body mass index cut offs for thinness, overweight and obesity. Pediatric Obesity2012;7:284‐94. ">Cole 2012</a>), often severe obesity prevalence is reported using country‐specific cut points making international comparisons difficult. Data from the USA (<a href="./references#CD012436-bbs2-0259" title="SkinnerAC , SkeltonJA . Prevalence and trends in obesity and severe obesity among children in the United States, 1999‐2012. JAMA Pediatrics2014;168(6):561‐6. [DOI: 10.1001/jamapediatrics.2014.21] ">Skinner 2014</a>) and England (<a href="./references#CD012436-bbs2-0195" title="EllsL , HancockC , CopleyVR , MeadE , DinsdaleH , KinraS , et al. Prevalence of severe childhood obesity in England: 2006‐2013. Archives of Disease in Childhood2015;100(7):631‐6. [DOI: 10.1136/archdischild‐2014‐307036] ">Ells 2015a</a>) have shown that severe paediatric obesity prevalence varies by socioeconomic status and ethnicity, and may result in greater risk of adverse cardio‐metabolic events and severe obesity in adulthood (<a href="./references#CD012436-bbs2-0219" title="KellyAS , BarlowSE , RaoG , IngeTH , HaymanLL , SteinbergerJ , et al. Severe obesity in children and adolescents: identification, associated health risks, and treatment approaches: a scientific statement From the American Heart Association. Circulation2013;128:1689‐712. ">Kelly 2013</a>). </p> <p>The prevalence of overweight and obese children is influenced by inequalities, where rates are higher in children from areas of high deprivation in high‐income countries (<a href="./references#CD012436-bbs2-0221" title="KnaiC , LobsteinT , DarmonN , RutterH , McKeeM . Socioeconomic patterning of childhood overweight status in Europe. International Journal of Environmental Research and Public Health2012;9(4):1472‐89. ">Knai 2012</a>; <a href="./references#CD012436-bbs2-0257" title="ShrewsburyV , WardleJ . Socioeconomic status and adiposity in childhood: a systematic review of cross‐sectional studies 1990‐2005. Obesity (Silver Spring)2008;16(2):275‐84. ">Shrewsbury 2008</a>), and from more affluent areas in low‐ or middle‐income countries (<a href="./references#CD012436-bbs2-0228" title="LobsteinT , BaurL , UauyR . Obesity in children and young people: a crisis in public health. Obesity Review2004;5(Suppl 1):4‐104. ">Lobstein 2004</a>; <a href="./references#CD012436-bbs2-0267" title="WangY , LimH . The global childhood obesity epidemic and the association between socio‐economic status and childhood obesity. International Review of Psychiatry2012;24(3):176‐88. ">Wang 2012</a>). Other variables are also likely to influence obesity prevalence including age, sex and ethnicity, with varying rates found in different groups in the USA (<a href="./references#CD012436-bbs2-0202" title="FreedmanDS , KhanLK , SerdulaMK , OgdenCL , DietzWH . Racial and ethnic differences in secular trends for childhood BMI, weight, and height. Obesity2006;14:301‐8. ">Freedman 2006</a>; <a href="./references#CD012436-bbs2-0259" title="SkinnerAC , SkeltonJA . Prevalence and trends in obesity and severe obesity among children in the United States, 1999‐2012. JAMA Pediatrics2014;168(6):561‐6. [DOI: 10.1001/jamapediatrics.2014.21] ">Skinner 2014</a>), England (<a href="./references#CD012436-bbs2-0214" title="Health and Social Care Information Centre. National Child Measurement Programme ‐ England, 2013‐14 school year. www.hscic.gov.uk/ (22 October 2016). ">HSCIC 2014</a>), and New Zealand (<a href="./references#CD012436-bbs2-0248" title="RajputN , TuohyP , MishraS , SmithA , TaylorB . Overweight and obesity in 4‐5‐year‐old children in New Zealand: results from the first 4 years (2009‐2012) of the B4School Check programme. Journal of Paediatrics and Child Health2014;51(3):334‐43. [DOI: 10.1111/jpc.12716] ">Rajput 2014</a>). </p> <section id="CD012436-sec-0038"> <h3 class="title" id="CD012436-sec-0038">Description of the condition</h3> <p>Being overweight or obese in childhood is associated with many conditions which may affect both physical and psychosocial health. Such conditions include hypertension, insulin resistance and hyperlipidaemia in obese children and adolescents, also including very young children (<a href="./references#CD012436-bbs2-0177" title="BoccaG , OngeringEC , StolkRP , SauerPJ . Insulin resistance and cardiovascular risk factors in 3‐ to 5‐year‐old overweight or obese children. Hormone Research in Paediatrics2013;80(3):201‐6. ">Bocca 2013</a>; <a href="./references#CD012436-bbs2-0201" title="FreedmanDS , DietzWH , SrinivasanSR , BerensonGS . The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study. Pediatrics1999;103(6 Pt 1):1175‐82. ">Freedman 1999</a>; <a href="./references#CD012436-bbs2-0250" title="ReillyJJ , MethvenE , McDowellZC , HackingB , AlexanderD , StewartL , et al. Health consequences of obesity. Archives of Disease in Childhood2003;88(9):748‐52. ">Reilly 2003</a>; <a href="./references#CD012436-bbs2-0268" title="WeissR , DziuraJ , BurgertTS , TamborlaneWV , TaksaliSE , YeckelCW , et al. Obesity and the metabolic syndrome in children and adolescents. New England Journal of Medicine2004;350(23):2362‐74. ">Weiss 2004</a>). The prevalence of type 2 diabetes has continued to increase in children and adolescents, with recent projections in the USA suggesting a potential quadrupling from 2010 to 2050 in the number of youths (aged less than 20 years old) with type 2 diabetes (<a href="./references#CD012436-bbs2-0216" title="ImperatoreG , BoyleJP , ThompsonTJ , CaseD , DabeleaD , HammanRF , et al. Projections of type 1 and type 2 diabetes burden in the U.S. population aged &lt;20 years through 2050: dynamic modeling of incidence, mortality, and population growth. Diabetes Care2012;35(12):2515‐20. ">Imperatore 2012</a>; <a href="./references#CD012436-bbs2-0245" title="Pinhas‐HamielO , ZeitlerP . The global spread of type 2 diabetes mellitus in children and adolescents. Journal of Pediatrics2005;146:693‐700. ">Pinhas‐Hamiel 2005</a>). Being overweight or obese in early childhood has also been linked to increased cardiovascular risk factors, such as high systolic blood pressure (<a href="./references#CD012436-bbs2-0197" title="FalaschettiE , HingoraniAD , JonesA , CharakidaM , FinerN , WhincupP , et al. Adiposity and cardiovascular risk factors in a large contemporary population of pre‐pubertal children. European Heart Journal2010;173(2):131‐9. ">Falaschetti 2010</a>), with such risks factors also being present in people with type 2 diabetes (<a href="./references#CD012436-bbs2-0230" title="MaahsDM , DanielsSR , deFerrantiSD , DichekHL , FlynnJ , GoldsteinBI , et al. Cardiovascular disease risk factors in youth with diabetes mellitus: a scientific statement from the American Heart Association. Circulation2014;130(17):1532‐58. ">Maahs 2014</a>). In addition medical conditions such as sleep apnoea, polycystic ovarian syndrome (PCOS) and poor pulmonary function have also been linked to childhood obesity (<a href="./references#CD012436-bbs2-0193" title="Dietz , WH . Health consequences of obesity in youth: childhood predictors of adult disease. Paediatrics1998;101(3S):518‐25. ">Dietz 1998</a>; <a href="./references#CD012436-bbs2-0194" title="EbbelingCB , PawlakDB , LudwigDS . Childhood obesity: public‐health crisis, common sense cure. Lancet2002;360(9331):473‐82. ">Ebbeling 2002</a>; <a href="./references#CD012436-bbs2-0228" title="LobsteinT , BaurL , UauyR . Obesity in children and young people: a crisis in public health. Obesity Review2004;5(Suppl 1):4‐104. ">Lobstein 2004</a>; <a href="./references#CD012436-bbs2-0250" title="ReillyJJ , MethvenE , McDowellZC , HackingB , AlexanderD , StewartL , et al. Health consequences of obesity. Archives of Disease in Childhood2003;88(9):748‐52. ">Reilly 2003</a>). Furthermore, childhood obesity has been shown to be strongly associated with nonalcoholic fatty liver disease (NAFLD), which is the most common cause of chronic liver disease in children and adolescents (<a href="./references#CD012436-bbs2-0172" title="AggarwalA , PuriK , ThangadaS , ZeinN , AlkhouriN . Nonalcoholic fatty liver disease in children: recent practice guidelines, where do they take us?. Current Pediatric Reviews2014;10(2):151‐61. ">Aggarwal 2014</a>; <a href="./references#CD012436-bbs2-0176" title="BerardisS , SokalE . Pediatric non‐alcoholic fatty liver disease: an increasing public health issue. European Journal of Pediatrics2014;173(2):131‐9. ">Berardis 2014</a>). </p> <p>The condition can also affect the child's mental health and lead to early discrimination, low self‐esteem and depression (<a href="./references#CD012436-bbs2-0193" title="Dietz , WH . Health consequences of obesity in youth: childhood predictors of adult disease. Paediatrics1998;101(3S):518‐25. ">Dietz 1998</a>; <a href="./references#CD012436-bbs2-0247" title="PuhlRM , LatnerJD . Stigma, obesity, and the health of the nation's children. Psychology Bulletin2007;133(4):557‐80. ">Puhl 2007</a>; <a href="./references#CD012436-bbs2-0262" title="Tang‐PeronardJL , HeitmannBL . Stigmatization of obese children and adolescents, the importance of gender. Obesity Reviews2008;9:1467‐89. ">Tang‐Peronard 2008</a>). There is also evidence that childhood obesity also tracks into adulthood (<a href="./references#CD012436-bbs2-0243" title="ParsonsTJ , PowerC , LoganS , SummerbellCD . Childhood predictors of adult obesity: a systematic review. International Journal of Obesity1999;23(Suppl 8):S1‐107. ">Parsons 1999</a>; <a href="./references#CD012436-bbs2-0258" title="SinghAS , MulderC , TwiskJW , vanMechelenW , ChinapawMJ . Tracking of childhood overweight into adulthood: a systematic review of the literature. Obesity Reviews2008;9(5):474‐88. ">Singh 2008</a>; <a href="./references#CD012436-bbs2-0269" title="WhitakerRC , WrightJA , PepeMS , SeidelKD , DietzWH . Predicting obesity in young adulthood from childhood and parental obesity. New England Journal of Medicine1997;337(13):869‐73. [MEDLINE: 97433004] ">Whitaker 1997</a>), and hence is associated with an increased risk of ill health in later life (<a href="./references#CD012436-bbs2-0251" title="ReillyJJ , KellyJ . Long‐term impact of overweight and obesity in childhood and adolescence on morbidity and premature mortality in adulthood: systematic review. International Journal of Obesity2011;35:891‐8. ">Reilly 2011</a>). </p> </section> <section id="CD012436-sec-0039"> <h3 class="title" id="CD012436-sec-0039">Description of the intervention</h3> <p>Since childhood obesity can potentially have serious consequences on a child's health and well‐being, it is very important to identify interventions which can treat obesity in both the short‐ and long‐term. The purposes of such interventions are similar to treatment in adults whereby the primary aims are: to reduce energy intake, increase energy expenditure and decrease sedentary behaviour. However, the child's age and baseline degree of obesity should be taken into consideration before deciding the type, length and intensity of the intervention. This will allow the intervention to be more tailored to the target population and potentially increase the chances of success and reduce the likelihood of adverse events. </p> <p>In recent years, only three drugs have been licensed for the treatment of adult obesity: rimonabant, sibutramine and orlistat. However, none of these were licensed for use in children (<a href="./references#CD012436-bbs2-0244" title="PetkarR , WrightN . Pharmacological management of obese child. Archives of Disease in Childhood ‐ Education and Practice2013;98:108‐12. [DOI: 10.1136/archdischild‐2011‐301127] ">Petkar 2013</a>). Rimonabant was withdrawn from the market due to psychiatric adverse events and sibutramine was suspended by the European Medicine Agency (EMA) and was withdrawn by the US Food and Drug Administration (FDA) in 2010 due to cardiovascular adverse effects; however, sibutramine is still licensed for treatment of obesity in Brazil. Orlistat has been approved by the FDA but only for people over the age of 12 years (<a href="./references#CD012436-bbs2-0256" title="Sherafat‐KazemzadehR , YanovskiSZ , YanovskiJA . Pharmacotherapy for childhood obesity: present and future prospects. International Journal of Obesity (London)2013;37(1):1‐15. [DOI: 10.1038/ijo.2012.144] ">Sherafat‐Kazemzadeh 2013</a>). In England, National Institute for Health and Care Excellence (NICE) guidance recommends that orlistat should only be used in children under 12 years old in exceptional circumstances where severe comorbidities exist. Moreover, in children who are 12 years or older, treatment is only recommended if there are physical comorbidities such as sleep apnoea or severe psychological comorbidities (<a href="./references#CD012436-bbs2-0238" title="National Institute for Health and Care Excellence. Obesity: identification, assessment and management of overweight and obesity in children, young people and adults. www.nice.org.uk/guidance/cg189/chapter/1‐recommendations#pharmacological‐interventions (accessed 5 August 2015). ">NICE 2014</a>). </p> <p>Metformin has been approved by the FDA to treat type 2 diabetes mellitus in both adults and children over the age of 10 years but does not have approval for treating obesity in children or adults (<a href="./references#CD012436-bbs2-0233" title="McDonaghM , SelphS , OzpinarA , FoleyC . Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. JAMA Pediatrics2014;168(2):178‐84. [DOI: 10.1001/jamapediatrics.2013.4200] ">McDonagh 2014</a>). However, an analysis of prescribing data in the UK in 2011 showed metformin has regularly been prescribed to treat childhood obesity, the main indication being PCOS (<a href="./references#CD012436-bbs2-0215" title="HsiaY , DawoudD , SutcliffeAG , VinerRM , KinraS , WongICK . Unlicensed use of metformin in children and adolescents in the UK. British Journal of Clinical Pharmacology2011;73(1):135‐9. [DOI: 10.1111/j.1365‐2125.2011.04063.x] ">Hsia 2011</a>). Other drugs which have also previously been used off‐licence to treat obesity in children and adolescents include antidepressants such as fluoxetine and bupropion (<a href="./references#CD012436-bbs2-0244" title="PetkarR , WrightN . Pharmacological management of obese child. Archives of Disease in Childhood ‐ Education and Practice2013;98:108‐12. [DOI: 10.1136/archdischild‐2011‐301127] ">Petkar 2013</a>). </p> <p>While weight loss alone may be of clinical and psychological benefit, additional health benefits may be achieved by the amelioration of obesity‐related disorders, such as hyperglycaemia in type 2 diabetes (<a href="./references#CD012436-bbs2-0241" title="PandeyA , ChawlaS , GuchhaitP . Type‐2 diabetes: current understanding and future perspectives. IUBMB Life2015;67(7):506‐13. ">Pandey 2015</a>), pain and mobility in osteoarthritis (<a href="./references#CD012436-bbs2-0273" title="WidhalmHK , SeemannR , HamboeckM , MittlboeckM , NeuholdA , FriedrichK , et al. Osteoarthritis in morbidly obese children and adolescents, an age‐matched controlled study. Knee Surgery, Sports Traumatology, Arthroscopy2016;24(3):644‐52. ">Widhalm 2016</a>), and improvement in obstructive sleep apnoea (<a href="./references#CD012436-bbs2-0236" title="NespoliL , CaprioglioA , BrunettiL , NosettiL . Obstructive sleep apnea syndrome in childhood. Early Human Development2013;89(Suppl 3):S33‐7. ">Nespoli 2013</a>). Weight loss may also reduce the risk factors for cardiovascular and metabolic disease (<a href="./references#CD012436-bbs2-0206" title="HalpernA , ManciniMC , MagalhãesME , FisbergM , RadominskiR , BertolamiMC , et al. Metabolic syndrome, dyslipidemia, hypertension and type 2 diabetes in youth: from diagnosis to treatment. Diabetology &amp; Metabolic Syndrome2010;2:55. [PUBMED: 20718958] ">Halpern 2010</a>), or even prevent the development of disease, for example type 2 diabetes (<a href="./references#CD012436-bbs2-0246" title="PowerC , Pinto PereiraSM , LawC , KiM . Obesity and risk factors for cardiovascular disease and type 2 diabetes: investigating the role of physical activity and sedentary behaviour in mid‐life in the 1958 British cohort. Atherosclerosis.2014;233(2):363‐9. ">Power 2014</a>). While registration of drugs usually does not require such clinical endpoints, people and health economic considerations increasingly demand evidence on more than just weight or BMI reduction, data that would be more difficult to establish in children and adolescents and have been poorly, if at all, studied. </p> <section id="CD012436-sec-0040"> <h4 class="title">Adverse effects of the intervention</h4> <p>One systematic review of pharmacological options for managing paediatric obesity stated that the most common adverse events when taking orlistat were gastrointestinal problems related to increased fat excretion (e.g. fatty or oily stools, increased defecation, soft stools, flatus, faecal leakage). Other adverse events included long‐term fat‐soluble deficiencies, decrease in vitamin D concentrations and asymptomatic gallstones (<a href="./references#CD012436-bbs2-0178" title="BolandCL , Brock HarrisJ , Harris , KB . Pharmacological management of obesity in pediatric patients. Annals of Pharmacotherapy2015;49(2):220‐32. [DOI: 10.1177/1060028014557859] ">Boland 2015</a>). The most frequent adverse events associated with metformin are gastrointestinal, some of which can be intolerable (<a href="./references#CD012436-bbs2-0232" title="McCreightLJ , BaileyCJ , PearsonER . Metformin and the gastrointestinal tract. Diabetologia2016;59(3):426‐35. ">McCreight 2016</a>). A change in dose or duration may resolve these adverse effects (<a href="./references#CD012436-bbs2-0233" title="McDonaghM , SelphS , OzpinarA , FoleyC . Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. JAMA Pediatrics2014;168(2):178‐84. [DOI: 10.1001/jamapediatrics.2013.4200] ">McDonagh 2014</a>). Common adverse effects of sibutramine included dry mouth, headaches, constipation and insomnia (<a href="./references#CD012436-bbs2-0183" title="CheungBM , CheungTT , SamaranayakeNR . Safety of antiobesity drugs. Therapeutic Advances in Drug Safety2013;4(4):171‐81. [DOI: 10.1177/2042098613489721] ">Cheung 2013</a>). However, the drug has also been linked to increased risk of nonfatal stroke or myocardial infarction, as shown in the Sibutramine Cardiovascular Outcomes (SCOUT) trial (<a href="./references#CD012436-bbs2-0217" title="JamesWP , CatersonID , CoutinhoW , FinerN , VanGaalLF , MaggioniAP , et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. New England Journal of Medicine2010;363(10):905‐17. ">James 2010</a>). Consequently, the drug was withdrawn from the market in numerous countries including the UK, USA and Australia. </p> </section> </section> <section id="CD012436-sec-0041"> <h3 class="title" id="CD012436-sec-0041">How the intervention might work</h3> <p>Sibutramine is a serotonin and norepinephrine reuptake inhibitor. It works by reducing hunger and improving satiety leading to decreased food intake (<a href="./references#CD012436-bbs2-0182" title="CatoiraN , NagelM , DiGirolamoG , GonzalezCD . Pharmacological treatment of obesity in children and adolescents: current status and perspectives. Expert Opinion on Pharmacotherapy2010;11(18):2973‐83. ">Catoira 2010</a>). Orlistat leads to the excretion of approximately 30% of ingested fat; it works by acting as a gastrointestinal lipase inhibitor (<a href="./references#CD012436-bbs2-0277" title="YanovskiSZ , YanovskiJA . Long‐term drug treatment of obesity: a systematic and clinical review. JAMA2014;311(1):74‐86. [DOI: 10.1001/jama.2013.281361] ">Yanovski 2014</a>). Metformin is a biguanide derivative which activates adenosine monophosphate‐activated protein kinase leading to the reduction of glucose production and absorption in the intestines and increasing insulin sensitivity. It is thought to reduce bodyweight by inhibiting fat cell lipogenesis and potentially may decrease food intake by increasing glucagon‐like peptide (<a href="./references#CD012436-bbs2-0231" title="MatsonKL , FallonRM . Treatment of obesity in children and adolescents. Journal of Pediatric Pharmacology and Therapeutics2012;17(1):45‐57. ">Matson 2012</a>). Fluoxetine is an antidepressant which works by inhibiting serotonin re‐uptake. It can result in weight loss by decreasing appetite and therefore inhibiting energy intake (<a href="./references#CD012436-bbs2-0278" title="YeZ , ChenL , YangZ , LiQ , HuangY , HeM , et al. Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta‐analysis of randomized placebo‐controlled trials. PLoS One2011;6(7):e21551. ">Ye 2011</a>). Hence, it is important to recognise that any drug that produces aversive taste or gastrointestinal adverse effects could produce weight loss by such adverse effects (<a href="./references#CD012436-bbs2-0205" title="HalfordJC , BoylandEJ , BlundellJE , KirkhamTC , HarroldJA . Pharmacological management of appetite expression in obesity. Nature Reviews. Endocrinology2010;6(5):255‐69. ">Halford 2010</a>). </p> </section> <section id="CD012436-sec-0042"> <h3 class="title" id="CD012436-sec-0042">Why it is important to do this review</h3> <p>In 2003, a systematic Cochrane Review was published entitled "Interventions for treating obesity in children" which assessed the effects of lifestyle interventions (dietary, physical activity, behavioural, or a combination of these) and included the analysis of childhood obesity treatment trials published up to July 2001 (<a href="./references#CD012436-bbs2-0280" title="SummerbellCD , AshtonV , CampbellKJ , EdmundsL , KellyS , WatersE . Interventions for treating obesity in children. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD001872] ">Summerbell 2003</a>). The second version of this Cochrane Review was published in 2009 providing an update to the 2003 review, and assessing the effects of pharmacological and surgical interventions (<a href="./references#CD012436-bbs2-0279" title="Oude LuttikhuisH , BaurL , JansenH , ShrewsburyVA , O'MalleyC , StolkRP , et al. Interventions for treating obesity in children. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD001872.pub2] ">Oude Luttikhuis 2009</a>). </p> <p>To reflect the rapid growth in this field, the third update to this review has been split across six reviews focusing on the following treatment approaches: "Surgery for the treatment of obesity in children and adolescents" (<a href="./references#CD012436-bbs2-0196" title="EllsLJ , MeadE , AtkinsonG , CorpeleijnE , RobertsK , VinerR , et al. Surgery for the treatment of obesity in children and adolescents. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD011740] ">Ells 2015b</a>); "Drug interventions for the treatment of obesity in children and adolescents"; "Parent‐only interventions for childhood overweight or obesity in children aged 5 to 11 years" (<a href="./references#CD012436-bbs2-0229" title="LovemanE , Al‐KhudairyL , JohnsonRE , RobertsonW , ColquittJL , MeadEL , et al. Parent‐only interventions for childhood overweight or obesity in children aged 5 to 11 years. Cochrane Database of Systematic Reviews2015, Issue 12. [DOI: 10.1002/14651858.CD012008] ">Loveman 2015</a>); "Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in preschool children up to the age of 6 years" (<a href="./references#CD012436-bbs2-0189" title="ColquittJL , LovemanE , O'MalleyC , AzevedoLB , MeadE , Al‐KhudairyL , et al. Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in preschool children up to the age of 6 years. Cochrane Database of Systematic Reviews2016, Issue 3. [DOI: 10.1002/14651858.CD012105] ">Colquitt 2016</a>); "Diet, physical activity and behavioural interventions for the treatment of overweight or obesity in school children from the age of 6 to 11 years"; and "Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in adolescents aged 12 to 17 years". This review in this series focuses on the efficacy of pharmacological interventions for obese children and adolescents. The review complements the Cochrane Review of "Long‐term pharmacotherapy for obesity and overweight" (<a href="./references#CD012436-bbs2-0240" title="PadwalRS , RuckerD , LiSK , CurioniC , LauDCW . Long‐term pharmacotherapy for obesity and overweight. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD004094.pub2] ">Padwal 2003</a>), which does not provide randomised controlled trial (RCT) data on pharmacological interventions for children and adolescents. </p> <p>The results of this current review and other systematic reviews in this series will provide information on which to underpin clinical guidelines and health policy on the treatment of children and adolescents who are overweight or obese. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012436-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012436-sec-0043">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012436-sec-0159">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012436-sec-0043"></div> <p>To assess the effects of drug interventions for the treatment of obesity in children and adolescents. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012436-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012436-sec-0044">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012436-sec-0160">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012436-sec-0044"></div> <section id="CD012436-sec-0045"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012436-sec-0046"> <h4 class="title">Types of studies</h4> <p>We included RCTs where the length of the intervention had to be at least three months and the length of follow‐up from baseline had to be a least six months. </p> </section> <section id="CD012436-sec-0047"> <h4 class="title">Types of participants</h4> <p>We included trials evaluating obese children and adolescents with a mean age of less than 18 years at the commencement of the intervention. We excluded trials with pregnant or critically ill participants. We excluded interventions that specifically dealt with the treatment of eating disorders or type 2 diabetes, or included participants with a secondary or syndromic cause of obesity. </p> </section> <section id="CD012436-sec-0048"> <h4 class="title">Types of interventions</h4> <p>We investigated any pharmacological intervention which aimed to treat paediatric obesity, using any of the following intervention versus control sequences, where the same letters indicate direct comparisons. </p> <section id="CD012436-sec-0049"> <h5 class="title">Intervention</h5> <p> <ul id="CD012436-list-0001"> <li> <p>(a) Pharmacological intervention.</p> </li> <li> <p>(b) Pharmacological intervention plus other therapy.</p> </li> </ul> </p> </section> <section id="CD012436-sec-0050"> <h5 class="title">Comparator</h5> <p> <ul id="CD012436-list-0002"> <li> <p>(a1) Placebo.</p> </li> <li> <p>(a2) Usual care.</p> </li> <li> <p>(b1) Placebo plus other therapy.</p> </li> <li> <p>(b2) Usual care plus other therapy.</p> </li> </ul> </p> <p>Concomitant therapies were required to be the same in both the intervention and comparator groups. </p> </section> <section id="CD012436-sec-0051"> <h5 class="title">Summary of specific exclusion criteria</h5> <p> <ul id="CD012436-list-0003"> <li> <p>Trials which included a growth hormone therapy as treatment for obesity.</p> </li> <li> <p>Trials which included pregnant participants.</p> </li> <li> <p>Trials which included participants who were critically ill.</p> </li> <li> <p>Trials where participants had a secondary or syndromic cause of obesity.</p> </li> <li> <p>Interventions that specifically dealt with the treatment of eating disorders or type 2 diabetes. </p> </li> <li> <p>Trials in which the aim was not to treat obesity in children or adolescents.</p> </li> <li> <p>Duration of intervention less than three months.</p> </li> <li> <p>Duration of follow‐up less than six months.</p> </li> </ul> </p> </section> </section> <section id="CD012436-sec-0052"> <h4 class="title">Types of outcome measures</h4> <section id="CD012436-sec-0053"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012436-list-0004"> <li> <p>Body mass index (BMI) and bodyweight.</p> </li> <li> <p>Adverse events.</p> </li> </ul> </p> </section> <section id="CD012436-sec-0054"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012436-list-0005"> <li> <p>Health‐related quality of life and self‐esteem.</p> </li> <li> <p>Body fat distribution.</p> </li> <li> <p>Behaviour change.</p> </li> <li> <p>Participants' views of the intervention.</p> </li> <li> <p>Morbidity.</p> </li> <li> <p>All‐cause mortality.</p> </li> <li> <p>Socioeconomic effects.</p> </li> </ul> </p> <section id="CD012436-sec-0055"> <h6 class="title">Timing of outcome measurement</h6> <p> <ul id="CD012436-list-0006"> <li> <p>BMI: defined as weight (kg) divided by height (m) squared, and bodyweight (kg): measured at baseline, 6, 12, 24 and more than 24 months. </p> </li> <li> <p>Adverse events: defined as an adverse outcome that occurred during or after the intervention but was not necessarily caused by it, and measured at any time during the trial. </p> </li> <li> <p>Health‐related quality of life and self‐esteem: evaluated by a validated instrument such as the Paediatric Quality of Life Inventory and measured at baseline, 6, 12, 24 and more than 24 months. </p> </li> <li> <p>Body fat distribution: defined by validated tools such as dual energy X‐ray absorptiometry (DEXA), waist circumference, skin fold thickness, waist‐to‐hip ratio and bioelectrical impedance analysis and measured at baseline, 6, 12, 24 and more than 24 months. </p> </li> <li> <p>Behaviour change: evaluated by a validated instrument and measured at baseline, 6, 12, 24 and more than 24 months. </p> </li> <li> <p>Participants' views of the intervention: defined as documented accounts from participant feedback and measured at baseline, 6, 12, 24 and more than 24 months. </p> </li> <li> <p>Morbidity: defined as illness or harm associated with the intervention and measured at baseline, 6, 12, 24 and more than 24 months. </p> </li> <li> <p>All‐cause mortality: defined as any death that occurred during or after the intervention and measured at any time during the trial. </p> </li> <li> <p>Socioeconomic effects: defined as a validated measure of socioeconomic status such as parental income or educational status and measured at baseline, 6, 12, 24 and more than 24 months. </p> </li> </ul> </p> </section> <section id="CD012436-sec-0056"> <h6 class="title">'Summary of findings' table</h6> <p>We presented a 'Summary of findings' table to report the following outcomes, listed according to priority. </p> <p> <ul id="CD012436-list-0007"> <li> <p>BMI and bodyweight.</p> </li> <li> <p>Adverse events.</p> </li> <li> <p>Health‐related quality of life.</p> </li> <li> <p>All‐cause mortality.</p> </li> <li> <p>Morbidity.</p> </li> <li> <p>Socioeconomic effects.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD012436-sec-0057"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012436-sec-0058"> <h4 class="title">Electronic searches</h4> <p>We searched the following sources on 15 March 2016 from inception to the specified date. </p> <p> <ul id="CD012436-list-0008"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) via Cochrane Register of Studies Online (CRSO). </p> </li> <li> <p>Ovid MEDLINE(R) In‐Process &amp; Other Non‐Indexed Citations and Ovid MEDLINE(R) (1946 to 15 March 2016). </p> </li> <li> <p>PubMed (subsets not available on Ovid) (15 March 2016).</p> </li> <li> <p>Embase 1974 to 2016 Week 11.</p> </li> <li> <p>LILACS (15 March 2016).</p> </li> <li> <p><a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> (15 March 2016). </p> </li> <li> <p>WHO International Clinical Trials Registry Platform (ICTRP; <a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) (15 March 2016). </p> </li> </ul> </p> <p>For detailed search strategies, see <a href="./appendices#CD012436-sec-0125">Appendix 1</a>. We continuously applied an email alert service for MEDLINE via OvidSP to identify newly published trials using the search strategy detailed in <a href="./appendices#CD012436-sec-0125">Appendix 1</a>. If we detected additional relevant key words during any of the electronic or other searches, we modified the electronic search strategies to incorporate these terms and documented the changes. We placed no restrictions on the language of publication when searching the electronic databases or reviewing reference lists of identified trials. </p> </section> <section id="CD012436-sec-0059"> <h4 class="title">Searching other resources</h4> <p>We attempted to identify other potentially eligible trials or ancillary publications by searching the reference lists of retrieved included trials, (systematic) reviews, meta‐analyses and health technology assessment reports. </p> </section> </section> <section id="CD012436-sec-0060"> <h3 class="title" id="CD012436-sec-0060">Data collection and analysis</h3> <section id="CD012436-sec-0061"> <h4 class="title">Selection of studies</h4> <p>To determine the trials to be assessed further, two review authors (of EM, LE, CO) independently scanned the abstract, title, or both, of every record retrieved by the searches. We obtained full‐text articles of all those trials deemed potentially relevant for inclusion. We resolved any differences in opinion by consultation of a third review author (of GA, EC, LE). If there was an outstanding issue with the trial, we added the article to those 'awaiting assessment' and we contacted trial authors for clarification. We presented an adapted PRISMA flow diagram of trial selection (<a href="#CD012436-fig-0001">Figure 1</a>) (<a href="./references#CD012436-bbs2-0227" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJPA , et al. The PRISMA statement for reporting systematic and meta‐analyses of studies that evaluate interventions: explanation and elaboration. PLoS Medicine2009;6(7):1‐28. [DOI: 10.1371/journal.pmed.1000100] ">Liberati 2009</a>). </p> <div class="figure" id="CD012436-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Trial flow diagram." data-id="CD012436-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial flow diagram.</p> </div> </div> </div> </section> <section id="CD012436-sec-0062"> <h4 class="title">Data extraction and management</h4> <p>For trials that fulfilled the inclusion criteria, two review authors (of EM, LE, GA, NF, EC, LB, CO) independently extracted key participant and intervention characteristics and reported data on efficacy outcomes and adverse events using standard data extraction templates. We resolved any disagreements by discussion, or, if required, by consultation with a third review author (of NF, EC, LB, GA) (for details see <a href="#CD012436-tbl-0002">Table 1</a>; <a href="./appendices#CD012436-sec-0126">Appendix 2</a>; <a href="./appendices#CD012436-sec-0127">Appendix 3</a>; <a href="./appendices#CD012436-sec-0128">Appendix 4</a>; <a href="./appendices#CD012436-sec-0129">Appendix 5</a>; <a href="./appendices#CD012436-sec-0130">Appendix 6</a>; <a href="./appendices#CD012436-sec-0131">Appendix 7</a>; <a href="./appendices#CD012436-sec-0132">Appendix 8</a>; <a href="./appendices#CD012436-sec-0133">Appendix 9</a>; <a href="./appendices#CD012436-sec-0134">Appendix 10</a>; <a href="./appendices#CD012436-sec-0135">Appendix 11</a>). </p> <div class="table" id="CD012436-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of trial populations</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Description of power and sample size calculation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Screened/eligible<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Safety<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ITT<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Finishing trial<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised finishing trial<br/> (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up time<sup>a</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Atabek 2008<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin + diet and physical activity advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + diet and physical activity advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Berkowitz 2003</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: behavioural programme + sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Powered to detect a 4% difference in % change in BMI between the 2 treatment groups with an SD of 5% (α = 0.05, β = 93%)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months (not including the 6‐month open‐label period where all participants received sibutramine) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: behavioural programme + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.2</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Berkowitz 2006</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: behavioural programme + sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Planned sample size was approximately 400 participants with a 3:1 randomization ratio of sibutramine to placebo. On the basis of previous 12‐month adult trials, we determined that 300 participants in the sibutramine group would be adequate to assess safety and exposure, allowing an overall dropout rate of approximately 50% and a probability that approximately 50% of participants receiving 10 mg of sibutramine would lose 10% or more of initial BMI at 6 months" </p> <p>"Although the protocol did not document a formal sample size calculation for efficacy, approximately 132 adolescents (99 in the sibutramine group and 33 in the placebo group) would allow a between‐group difference in BMI of 2 kg/m<sup>2</sup>, with 90% power (2‐sided level of 0.05) to be statistically significant, assuming a common SD of 3 kg/m<sup>2</sup>)"<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: behavioural programme + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.5</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Chanoine 2005</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: orlistat + diet + exercise + behaviour therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"We planned to enroll at least 450 individuals to provide more than 80% power to detect a difference of 1 BMI unit, assuming a 30% dropout rate" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>54 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + diet + exercise + behaviour therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.3</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>539</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>533</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Clarson 2009</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin + lifestyle intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: lifestyle intervention only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.4</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Franco 2014</b> </p> <p><b>(cross‐over trial)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: sibutramine + dietary guidance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>13 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + dietary guidance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>‐</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Freemark 2001</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.2</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Garcia‐Morales 2006</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: sibutramine + diet + exercise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13 participants per group (expectations: mean loss of 7.5 kg (SD 5.3) in the sibutramine group vs 3.6 kg (SD 4.5) in the placebo group)<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + diet + exercise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.0</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Godoy‐Matos 2005</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: sibutramine + hypocaloric diet + exercise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>24 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + hypocaloric diet + exercise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.3</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Kendall 2013</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin + healthy lifestyle advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"The target recruitment was 140 patients, based on a power calculation using the results of a previous study. A standard power calculation was used to detect a reduction in BMI of 0.15 kg/m<sup>2</sup> (SD 0.3). Sixty‐four participants in each group give a statistical power of 80% for a t test at the 5% significance level. This was rounded up to allow for some loss to follow‐up but recognizing that adjustment using multifactorial analysis would likely enhance the trial power by an unpredictable amount"<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + healthy lifestyle advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Maahs 2006</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: orlistat + diet and exercise therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"We determined that a clinically important mean difference in decrease in BMI between the orlistat and placebo groups would be 2.0 kg/m<sup>2</sup> at 6 months and used an SD of 1.8. On the basis of this approach, a sample size of 15 subjects per group would be adequate to detect a 2.0 kg/m<sup>2</sup> difference in Student’s t test with 80% power and alpha = 0.05. In order to allow for a 25% dropout rate, 20 subjects were randomized to each group"<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + diet and exercise therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.0</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Mauras 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin + diet/exercise intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Differences in hsCRP and fibrinogen concentrations at 6 months were the primary outcomes. An n = 42 completed subjects provided &gt; 90 % power to detect significant changes" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: diet/exercise intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.3</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>NCT00001723</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: orlistat + behavioural weight loss programme</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + behavioural weight loss programme</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Ozkan 2004</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: conventional treatment (nutritional and lifestyle modification programmes) + orlistat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>5 to 15 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: conventional treatment: nutritional and lifestyle modification programmes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.0</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Prado 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin + nutritional guide and exercise programme</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 participants were required per intervention group (SD 0.4; difference of 0.6, P &lt; 0.05, power = 90%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>41/26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + nutritional guide and exercise programme</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><b>Rezvanian 2010</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: metformin + diet and physical activity advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>"By considering alpha = 0.05 and a power level of 0.8, the sample size was calculated as 160, and by considering the attrition during the follow‐up, we increased it to 180" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>24 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: fluoxetine + diet and physical activity advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I3: metformin and fluoxetine + diet and physical activity advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + diet and physical activity advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.3</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Srinivasan 2006</b> </p> <p><b>(cross‐over trial)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin + "standardised information on healthy eating and exercise"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>‐</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + "standardised information on healthy eating and exercise"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>‐</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Van Mil 2007</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: sibutramine + energy‐restricted diet and exercise plan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"The number of patients required per treatment group to detect a difference between treatment groups in mean change in BMI at endpoint intervention of 1.0 kg/m<sup>2</sup>, based on an estimate of variance (sd) of 0.65, an overall significance level of 5%, and a power of 90%, was nine. Allowing a drop‐out rate of 25%, the number of patients needed in each group was 12"<sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>24 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + energy‐restricted diet and exercise plan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.0</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Wiegand 2010</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin + lifestyle intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Since a clinically significant effect was defined as a decrease in HOMA‐IR by ‐1, two groups of 37 patients had to be included in the study to achieve a power of 0.9 with a α value of 0.05" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + lifestyle intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.3</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Wilson 2010</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin + lifestyle intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Assuming an SD of 1.9 for BMI change, an enrolled sample of 72 provided 80% power to detect a differential of 1.46 between treatment arms or between sexes and 1.75 between white subjects and others"<sup>i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>100 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + lifestyle intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.0</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Yanovski 2011</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin + dietitian‐administered weight‐reduction programme</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"A total sample size of 60 participants would detect a between‐group difference of 0.09 BMI SD score units (approximately equivalent to a 2 kg/m<sup>2</sup> difference) with 80% power. Participant accrual was set at 100 participants to allow as much as 40% loss to follow‐up"<sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months (not including the 6‐month open‐label phase)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + dietitian‐administered weight‐reduction programme</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.1</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b><i>Grand total</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>All interventions<sup>k</sup> </i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>1395</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>1153</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>All comparators<sup>k</sup> </i> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>817</i> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>665</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>All interventions and comparators<sup>k</sup> </i> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>2484</i> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>1851</i> </b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Duration of intervention and follow‐up under randomised conditions until end of trial.<br/> <sup>b</sup>Unclear from the publication on the number which completed the trial and hence number of dropouts.<br/> <sup>c</sup>Actual treatment difference between intervention groups was 4.5% reduction in BMI.<br/> <sup>d</sup>Actual treatment difference between intervention groups at 12 months was 2.9 kg/m<sup>2</sup>.<br/> <sup>e</sup>Actual weight loss was 7.3 kg in the sibutramine group vs 4.3 kg in the placebo group.<br/> <sup>f</sup>Actual adjusted treatment difference at 6 months was ‐1.07 kg/m<sup>2</sup>.<br/> <sup>g</sup>Actual treatment difference between intervention groups at 6 months was 0.5 kg/m<sup>2</sup>.<br/> <sup>h</sup>Actual treatment difference between intervention groups at end of intervention (12 weeks) was 0.4 kg/m<sup>2</sup> and at end of follow‐up (24 weeks) was 1.0 kg/m<sup>2</sup>.<br/> <sup>i</sup>Actual treatment difference between intervention groups after 48 weeks was 1.1 kg/m<sup>2</sup>.<br/> <sup>j</sup>Actual treatment difference between intervention groups at 6 months for BMI z score was 0.07.<br/> <sup>k</sup>Numbers for interventions and comparators do not add up to 'all interventions and comparators' because several trials did not provide information on randomised participants per intervention/comparator group but only the total number of randomised participants. </p> <p>"‐" denotes not reported.</p> <p>BMI: body mass index; C: comparator; hsCRP: high sensitivity C‐reactive protein; HOMA‐IR: homeostasis model assessment for insulin resistance index; I: intervention; ITT: intention‐to‐treat; n: number of participants; SD: standard deviation. </p> </div> </div> <p>We provided information, including trial identifier, about potentially relevant ongoing trials in the <a href="./references#CD012436-sec-0152" title="">Characteristics of ongoing studies</a> table and in <a href="./appendices#CD012436-sec-0129">Appendix 5</a>. We tried to obtain the protocol of each included trial, either in trial registers or in publications of trial designs, or both, and specified the data <a href="./appendices#CD012436-sec-0129">Appendix 5</a>. </p> <p>We sent an email to all authors of included trials to enquire whether they were willing to answer questions regarding their trials. <a href="./appendices#CD012436-sec-0136">Appendix 12</a> shows the results of this survey. Thereafter, we sought relevant missing information on the trial from the primary author(s) of the article, if required. </p> <section id="CD012436-sec-0063"> <h5 class="title">Dealing with duplicate and companion publications</h5> <p>In the event of duplicate publications, companion documents or multiple reports of a primary trial, we tried to maximise yield of information by collating all available data and used the most complete data set aggregated across all known publications. In case of doubt, we gave priority to the publication reporting the longest follow‐up associated with our primary or secondary outcomes. </p> </section> </section> <section id="CD012436-sec-0064"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (of EM, LE, GA, NF, EC, LB, CO) independently assessed the risk of bias of each included trial. We resolved possible disagreements by consensus, or with consultation of a third party. In cases of disagreement, the rest of the group were consulted and a judgement was made based on consensus. </p> <p>We assessed risk of bias using Cochrane's 'Risk of bias' tool (<a href="./references#CD012436-bbs2-0211" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>; <a href="./references#CD012436-bbs2-0212" title="HigginsJPT , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928. ">Higgins 2011b</a>). We used the following criteria. </p> <p> <ul id="CD012436-list-0009"> <li> <p>Random sequence generation (selection bias).</p> </li> <li> <p>Allocation concealment (selection bias).</p> </li> <li> <p>Blinding (performance bias and detection bias), separated for blinding of participants and personnel and blinding of outcome assessment. </p> </li> <li> <p>Incomplete outcome data (attrition bias).</p> </li> <li> <p>Selective reporting (reporting bias).</p> </li> <li> <p>Other bias.</p> </li> </ul> </p> <p>We assessed outcome reporting bias by integrating the results of 'Examination of outcome reporting bias' (<a href="./appendices#CD012436-sec-0130">Appendix 6</a>), 'Matrix of trial endpoints (publications trial documents)' (<a href="./appendices#CD012436-sec-0129">Appendix 5</a>), and section 'Outcomes (outcomes reported in abstract of publication)' of the <a href="./references#CD012436-sec-0149" title="">Characteristics of included studies</a> table (<a href="./references#CD012436-bbs2-0220" title="KirkhamJJ , DwanKM , AltmanDG , GambleC , DoddS , SmythR , et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ2010;340:c365. [DOI: 10.1136/bmj.c365] ">Kirkham 2010</a>). This analysis formed the basis for the judgement of selective reporting (reporting bias). </p> <p>We judged risk of bias criteria as 'low risk', 'high risk' or 'unclear risk' and evaluated individual bias items as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012436-bbs2-0211" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). We presented a 'Risk of bias' graph and a 'Risk of bias' summary figure. </p> <p>We assessed the impact of individual bias domains on trial results at endpoint and trial levels. </p> <p>For blinding of participants and personnel (performance bias), detection bias (blinding of outcome assessors) and attrition bias (incomplete outcome data), we intended to evaluate risk of bias separately for subjective and objective outcomes (<a href="./references#CD012436-bbs2-0213" title="HróbjartssonA , ThomsenAS , EmanuelssonF , TendalB , HildenJ , BoutronI , et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. Canadian Medical Association Journal2013;185(4):E201‐11. ">Hróbjartsson 2013</a>). We considered the implications of missing outcome data from individual participants. </p> <p>We defined the following endpoints as self‐reported outcomes.</p> <p> <ul id="CD012436-list-0010"> <li> <p>All self‐reported data such as a self‐reported health‐related quality of life questionnaires.</p> </li> </ul> </p> <p>We defined the following endpoints as investigator‐assessed outcomes.</p> <p> <ul id="CD012436-list-0011"> <li> <p>All measured data such as assessor measured height and weight.</p> </li> </ul> </p> </section> <section id="CD012436-sec-0065"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed continuous data as mean differences (MD) with 95% confidence intervals (CI). We expressed dichotomous data as odds ratios (ORs) or risk ratios (RRs) with 95% CIs. We used Comprehensive Meta Analysis (CMA) version 3 and Review Manager 5 (<a href="./references#CD012436-bbs2-0252" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) to conduct the meta‐analyses. </p> </section> <section id="CD012436-sec-0066"> <h4 class="title">Unit of analysis issues</h4> <p>We tried to consider the level at which randomisation occurred, such as cross‐over trials, cluster‐randomised trials and multiple observations for the same outcome. </p> </section> <section id="CD012436-sec-0067"> <h4 class="title">Dealing with missing data</h4> <p>We obtained relevant missing data from trial authors, if feasible, and evaluated important numerical data such as screened, eligible, randomised participants as well as intention‐to‐treat (ITT), as‐treated and per‐protocol (PP) populations. We investigated attrition rates, for example dropouts, losses to follow‐up and withdrawals, and critically appraised issues of missing data and imputation methods (e.g. last observation carried forward (LOCF)). </p> <p>Where standard deviations (SD) for outcomes were not reported, we imputed these values by assuming the SD of the missing outcome to be the mean of the SDs from those trials where this information was reported. We investigated the impact of imputation on meta‐analyses by means of sensitivity analyses. </p> </section> <section id="CD012436-sec-0068"> <h4 class="title">Assessment of heterogeneity</h4> <p>In the event of substantial clinical or methodological heterogeneity, we did not report trial results as meta‐analytically pooled effect estimates. We identified heterogeneity by visual inspection of the forest plots and by using a standard Chi<sup>2</sup> test with a significance level of α = 0.1, in view of the low power of this test. We examined heterogeneity using the I<sup>2</sup> statistic, which quantifies inconsistency across trials to assess the impact of heterogeneity on the meta‐analysis (<a href="./references#CD012436-bbs2-0208" title="HigginsJPT , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21(11):1539‐58. ">Higgins 2002</a>; <a href="./references#CD012436-bbs2-0209" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>), where an I<sup>2</sup> statistic of 75% or more indicates a considerable level of inconsistency (<a href="./references#CD012436-bbs2-0211" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). We also calculated Tau<sup>2</sup>, another statistic that provides information about heterogeneity. </p> <p>When we found heterogeneity, we attempted to determine potential reasons for it by examining individual trial and subgroup characteristics. </p> <p>We expected the following characteristics to introduce clinical heterogeneity.</p> <p> <ul id="CD012436-list-0012"> <li> <p>Differences in the age of trial population.</p> </li> <li> <p>Differences in the trial population demographics.</p> </li> <li> <p>Differences in the types of drugs.</p> </li> <li> <p>Differences in BMI at baseline.</p> </li> </ul> </p> </section> <section id="CD012436-sec-0069"> <h4 class="title">Assessment of reporting biases</h4> <p>If we included 10 trials or more for a given outcome, we used funnel plots to assess small‐trial effects. Due to several explanations for funnel plot asymmetry, we interpreted results carefully (<a href="./references#CD012436-bbs2-0260" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta‐analyses of randomised controlled trials. BMJ2011;343:d4002. ">Sterne 2011</a>). </p> </section> <section id="CD012436-sec-0070"> <h4 class="title">Data synthesis</h4> <p>Unless there was good evidence for homogeneous effects across trials, we primarily summarised low risk of bias data by means of a random‐effects model (<a href="./references#CD012436-bbs2-0275" title="WoodL , EggerM , GluudLL , SchulzKF , JuniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336(7644):601‐5. ">Wood 2008</a>). We interpreted random‐effects meta‐analyses with due consideration of the whole distribution of effects, ideally by presenting a prediction interval (<a href="./references#CD012436-bbs2-0210" title="HigginsJPT , ThompsonSG , SpiegelhalterDJ . A re‐evaluation of random‐effects meta‐analysis. Journal of the Royal Statistical Society. Series A, (Statistics in Society)2009;172(1):137‐59. ">Higgins 2009</a>). A prediction interval specifies a predicted range for the true treatment effect in an individual trial (<a href="./references#CD012436-bbs2-0253" title="RileyRD , HigginsJP , DeeksJJ . Interpretation of random effects meta‐analyses. BMJ2011;342:d549. ">Riley 2011</a>). In addition, we performed statistical analyses according to the statistical guidelines referenced in the latest version of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012436-bbs2-0211" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). </p> <section id="CD012436-sec-0071"> <h5 class="title">Quality of evidence</h5> <p>We presented the overall certainty of the evidence for each outcome specified under 'Types of outcome measures: Summary of findings table' according to the GRADE approach which considers issues not only related to internal validity (risk of bias, inconsistency, imprecision, publication bias) but also to external validity such as directness of results<i>.</i> Two review authors (EM, GA) independently rated the certainty for each outcome. We presented a summary of the evidence in <a href="./full#CD012436-tbl-0001">summary of findings Table for the main comparison</a>, which provides key information about the best estimate of the magnitude of the effect, in relative terms and absolute differences for each relevant comparison of alternative management strategies, numbers of participants and trials addressing each important outcome and the rating of the overall confidence in effect estimates for each outcome. We created the <a href="./full#CD012436-tbl-0001">summary of findings Table for the main comparison</a> based on the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012436-bbs2-0211" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). We presented results on the outcomes as described in <a href="#CD012436-sec-0052">Types of outcome measures</a>. If meta‐analysis was not possible, we presented results in a narrative form in <a href="./full#CD012436-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>In addition, we established an appendix 'Checklist to aid consistency and reproducibility of GRADE assessments' (<a href="./references#CD012436-bbs2-0235" title="MeaderN , KingK , LlewellynA , NormanG , BrownJ , RodgersM , et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews2014;3:82. ">Meader 2014</a>) to help with standardisation of 'Summary of findings' tables (<a href="./appendices#CD012436-sec-0137">Appendix 13</a>). </p> </section> </section> <section id="CD012436-sec-0072"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out the following subgroup analyses and investigated interactions.</p> <p> <ul id="CD012436-list-0013"> <li> <p>Length of follow‐up.</p> </li> <li> <p>Impact and nature of maintenance periods.</p> </li> <li> <p>The impact of comparator/control: whether concomitant therapy or no treatment (true control). </p> </li> <li> <p>The impact of population demographics.</p> </li> </ul> </p> </section> <section id="CD012436-sec-0073"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to performed sensitivity analyses to explore the influence of the following factors on effect size. </p> <p> <ul id="CD012436-list-0014"> <li> <p>Restricting the analysis to published trials.</p> </li> <li> <p>Restricting the analysis considering risk of bias, as specified in the <a href="#CD012436-sec-0064">Assessment of risk of bias in included studies</a> section. </p> </li> <li> <p>Restricting the analysis to very long or large trials (more than 300 participants in total) to establish how much they dominated the results. </p> </li> <li> <p>Restricting the analysis to trials using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), country. </p> </li> </ul> </p> <p>We also tested the robustness of the results by repeating the analysis using different measures of effect size (RR, OR, etc.) and different statistical models (fixed‐effect and random‐effects models). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012436-sec-0074" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012436-sec-0074"></div> <section id="CD012436-sec-0075"> <h3 class="title">Description of studies</h3> <p>For a detailed description of trials, see the <a href="./references#CD012436-sec-0149" title="">Characteristics of included studies</a>, <a href="./references#CD012436-sec-0150" title="">Characteristics of excluded studies</a> and <a href="./references#CD012436-sec-0152" title="">Characteristics of ongoing studies</a> tables. </p> <section id="CD012436-sec-0076"> <h4 class="title">Results of the search</h4> <p>Our comprehensive literature searches identified 4995 records; from these, 199 full‐text papers or clinical trial records were identified for further examination. We excluded trials based on their titles or abstracts because they did not meet the inclusion criteria or were not relevant to the question under trial (see <a href="#CD012436-fig-0001">Figure 1</a> for the amended PRISMA flow diagram). After screening the full text of the selected publications, 21 completed trials (33 publications) met the inclusion criteria and were included in the qualitative synthesis of this review. All trials were published in English apart from <a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a> (Portuguese) and <a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a> (Spanish). We contacted all trial authors of the included trials and received a reply from all but four authors (<a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a>; <a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0014" title="OzkanB , BereketA , TuranS , KeskinS . Addition of orlistat to conventional treatment in adolescents with severe obesity. European Journal of Pediatrics2004;163(12):738‐41. ">Ozkan 2004</a>). We sought additional information from the authors of all 21 trials, 12 authors responded to these requests and provided further data (<a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>; <a href="./references#CD012436-bbs2-0005" title="ClarsonCL , MahmudFH , BakerJE , ClarkHE , MckayWM , SchauteetVD , et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine2009;36(1):141‐6. [DOI: 10.1007/s12020‐009‐9196‐9] ">Clarson 2009</a>; <a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a>; <a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>; <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a>; <a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>; <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a>; <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>; <a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a>; <a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a>; <a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a>; <a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a>). We also identified eight ongoing trials, and an additional seven trials were placed in the 'awaiting classification' section because we could not source the full publication, the trial was completed but there was not yet enough information to include it in this review or the publication was identified when a final draft of the review had been completed (<a href="./references#CD012436-bbs2-0162" title="van derAaMP , ElstMA , vanMilEG , KnibbeCA , van derVorstMM . Metformin: an efficacy, safety and pharmacokinetic study on the short‐term and long‐term use in obese children and adolescents ‐ study protocol of a randomized controlled study. Trials2014;15:207. van derAaMP , ElstMA , van deGardeEM , vanMilEG , KnibbeCA , van derVorstMM . Long‐term treatment with metformin in obese, insulin‐resistant adolescents: results of a randomized double‐blinded placebo‐controlled trial. Nutrition &amp; Diabetes2016;6(8):e228. [DOI: 10.1038/nutd.2016.37] ">NCT01487993</a>). </p> </section> <section id="CD012436-sec-0077"> <h4 class="title">Included studies</h4> <p>A detailed description of the characteristics of included trials is presented elsewhere (see <a href="./references#CD012436-sec-0149" title="">Characteristics of included studies</a>; <a href="./appendices#CD012436-sec-0126">Appendix 2</a>; <a href="./appendices#CD012436-sec-0127">Appendix 3</a>; <a href="./appendices#CD012436-sec-0128">Appendix 4</a>). The following is a succinct overview. </p> <section id="CD012436-sec-0078"> <h5 class="title">Source of data</h5> <p>The literature search identified all 21 included trials in the review and all but one (<a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>) were published trials. Ten out of 21 trials were included in the previous review (<a href="./references#CD012436-bbs2-0279" title="Oude LuttikhuisH , BaurL , JansenH , ShrewsburyVA , O'MalleyC , StolkRP , et al. Interventions for treating obesity in children. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD001872.pub2] ">Oude Luttikhuis 2009</a>), and information relating to these 10 trials was extracted from the 2009 review ‐ two review authors extracted any missing information from the publication. All ongoing trials were found from searching online clinical trial registers. </p> </section> <section id="CD012436-sec-0079"> <h5 class="title">Comparisons</h5> <p>Of the 21 included trials, 11 used metformin in their intervention arm; four of these trials gave metformin plus a behaviour changing programme to the intervention group and used a placebo plus a behaviour changing programme in the comparator group (<a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a>; <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>). Two trials compared metformin plus a behaviour changing programme against a behaviour changing programme alone without using a placebo (<a href="./references#CD012436-bbs2-0005" title="ClarsonCL , MahmudFH , BakerJE , ClarkHE , MckayWM , SchauteetVD , et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine2009;36(1):141‐6. [DOI: 10.1007/s12020‐009‐9196‐9] ">Clarson 2009</a>; <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a>). Four trials compared metformin plus a behaviour changing intervention against placebo plus a behaviour changing intervention (<a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a>; <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a>; <a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a>). <a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a> also had two additional intervention arms: metformin plus fluoxetine plus healthy eating plus physical activity advice; and fluoxetine plus healthy eating plus physical activity advice. The remaining trial compared metformin with placebo; hence, there was no lifestyle component included in either arm (<a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>). </p> <p>Six trials used sibutramine as the pharmacological intervention; three trials compared sibutramine plus a behaviour changing programme with placebo plus a behaviour changing programme (<a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a>). The other three trials compared sibutramine plus dietary/exercise advice with placebo plus dietary/exercise advice (<a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a>; <a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>; <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a>). </p> <p>Four trials investigated orlistat. <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>, <a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>, and <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a> examined orlistat plus a behaviour changing intervention versus placebo plus a behaviour changing intervention. <a href="./references#CD012436-bbs2-0014" title="OzkanB , BereketA , TuranS , KeskinS . Addition of orlistat to conventional treatment in adolescents with severe obesity. European Journal of Pediatrics2004;163(12):738‐41. ">Ozkan 2004</a> did not include a placebo in their comparator group; hence, they compared orlistat plus a behaviour changing intervention with a behaviour changing intervention only. </p> </section> <section id="CD012436-sec-0080"> <h5 class="title">Overview of trial populations</h5> <p>A total of 2484 children and adolescents participated in the 21 included trials. A total of 1851 participants finished the trial (74.5%) and hence we measured at the study's endpoint. In 10 studies, the dropout rates were higher in the placebo group than the intervention group, potentially showing some dissatisfaction with the control condition. The individual trial sample size ranged from 24 to 539 participants. </p> <p>The 11 metformin trials included 885 participants. The individual trial sample size ranged from 26 to 155 participants. One metformin trial also included two additional intervention arms of fluoxetine and fluoxetine plus metformin (45 randomised participants in each intervention arm). </p> <p>The six sibutramine trials included 778 participants. The individual trial sample size ranged from 24 to 498 participants. </p> <p>The four orlistat trials included 821 participants. The individual trial sample size ranged from 40 to 539 participants. </p> </section> <section id="CD012436-sec-0081"> <h5 class="title">Trial design</h5> <p>Trials were RCTs. Nineteen trials adopted a parallel group superiority design and two were cross‐over trials (<a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a>; <a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a>). All but three trials used a placebo comparator (<a href="./references#CD012436-bbs2-0005" title="ClarsonCL , MahmudFH , BakerJE , ClarkHE , MckayWM , SchauteetVD , et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine2009;36(1):141‐6. [DOI: 10.1007/s12020‐009‐9196‐9] ">Clarson 2009</a>; <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a>; <a href="./references#CD012436-bbs2-0014" title="OzkanB , BereketA , TuranS , KeskinS . Addition of orlistat to conventional treatment in adolescents with severe obesity. European Journal of Pediatrics2004;163(12):738‐41. ">Ozkan 2004</a>). Five trials were multicentred (<a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>; <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>), with the number of centres ranging from two (<a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>) to 33 (<a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>). In terms of blinding, 14 trials were double‐blinded for participants and personnel (<a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>; <a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a>; <a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>; <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a>; <a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>; <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>; <a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a>; <a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a>; <a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a>; <a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>), no trials were single‐blinded for participants, and four trials did not define blinding (<a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a>; <a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>; <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0014" title="OzkanB , BereketA , TuranS , KeskinS . Addition of orlistat to conventional treatment in adolescents with severe obesity. European Journal of Pediatrics2004;163(12):738‐41. ">Ozkan 2004</a>). Thirteen trials blinded outcome assessors (<a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>; <a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a>; <a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>; <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a>; <a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>; <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>; <a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a>; <a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a>; <a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a>; <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>). Trials were published between the 2001 and 2014; all but one sibutramine trial were published before the drug was withdrawn by the FDA ‐ <a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a> was conducted in Brazil where the drug is still licensed. All metformin trials were published between 2006 and 2012 apart from <a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>. Orlistat trials were published between 2004 and 2006, but one trial did not have any publications available and only posted results on a clinical trial website and in a conference abstract (<a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>). </p> <p>The duration of interventions ranged from 12 weeks to 17 months, with a mean duration of 28 weeks. The duration of follow‐up (from end of intervention) ranged from 0 to 52 weeks, with a mean follow‐up period of 12 weeks. Participants in nine trials received the intervention/comparator for six months with no additional follow‐up; in three trials, participants received the intervention/comparator for six months, which was then followed by an open‐label period for six months (<a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>); two trials received the intervention for 12 months with no additional follow‐up (<a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>); two cross‐over trials included a six‐month intervention or control condition followed by a washout period, then each participant crossed over into the alternative condition for an additional six months (<a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a>; <a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a>); three trials included an intervention/comparator period for three months (or 12 weeks) then a follow‐up period for an additional three months (or 12 weeks) (<a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a><a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a>; <a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a>); one trial gave the intervention or comparator condition for 48 weeks, then included an additional follow‐up period for another 48 weeks (<a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>); and finally in one trial the length of the intervention and follow‐up varied across participants (<a href="./references#CD012436-bbs2-0014" title="OzkanB , BereketA , TuranS , KeskinS . Addition of orlistat to conventional treatment in adolescents with severe obesity. European Journal of Pediatrics2004;163(12):738‐41. ">Ozkan 2004</a>). </p> <p>Five trials had a run‐in period, of which three included a placebo run‐in phase (<a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>; <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>), with a duration varying from two to four weeks; <a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a> included 48‐hour inpatient tests as their run‐in period; two trial gave dietetic advice/counselling (<a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>; <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a>); <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a> also included a lifestyle modification programme in their run‐in period. Outcomes were not assessed in these run‐in periods. Furthermore, three trials included an open‐label phase six months after randomisation where both groups received the drug intervention (<a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>); these open‐label phases were not included in our analyses. Participants in one of these trials were also followed up for two years after the open‐label phase (<a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>). None of the included trials were terminated before regular end; however, two trials that we identified from ClinicalTrials.gov were terminated before enrolment and have been placed in the excluded trials section (see <a href="./references#CD012436-sec-0150" title="">Characteristics of excluded studies</a> table). </p> </section> <section id="CD012436-sec-0082"> <h5 class="title">Settings</h5> <p>Nine of the 21 trials were conducted in the USA (<a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>; <a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>; <a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>; <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a>; <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>). The other trials were completed in Turkey (<a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a>; <a href="./references#CD012436-bbs2-0014" title="OzkanB , BereketA , TuranS , KeskinS . Addition of orlistat to conventional treatment in adolescents with severe obesity. European Journal of Pediatrics2004;163(12):738‐41. ">Ozkan 2004</a>), Canada (<a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>; <a href="./references#CD012436-bbs2-0005" title="ClarsonCL , MahmudFH , BakerJE , ClarkHE , MckayWM , SchauteetVD , et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine2009;36(1):141‐6. [DOI: 10.1007/s12020‐009‐9196‐9] ">Clarson 2009</a>), Brazil (<a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a>; <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a>), Mexico (<a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>), the UK (<a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>), Australia (<a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a>), Chile (<a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a>), Iran (<a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a>), the Netherlands (<a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a>), Germany (<a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>), and Switzerland (<a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>). All trials were performed in an outpatient setting apart from three trials which had both an inpatient and outpatient setting (<a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>; <a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>). </p> </section> <section id="CD012436-sec-0083"> <h5 class="title">Participants</h5> <p>The participating population consisted of the following: mainly obese children or adolescents (<a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a> also included overweight participants). The mean age of the participants in the trials ranged from 10.1 to 16.3 years with only two trials having a mean age less than 12 years old (<a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>). Two studies required all participants to be postmenarchal (<a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a>), while <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a> only included children who were prepubertal or early pubertal. Fifteen trials included participants from high‐income countries, and six recruited participants from middle‐income countries (<a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a>; <a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a>; <a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>; <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a>; <a href="./references#CD012436-bbs2-0014" title="OzkanB , BereketA , TuranS , KeskinS . Addition of orlistat to conventional treatment in adolescents with severe obesity. European Journal of Pediatrics2004;163(12):738‐41. ">Ozkan 2004</a>; <a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a>) ‐ based on the World Bank list of economies July 2015 (<a href="./references#CD012436-bbs2-0276" title="The WorldBank . Country and Lending Groups. data.worldbank.org/about/country‐and‐lending‐groups (accessed 5 August 2015). ">World Bank 2015</a>). Ethnic groups were distributed as follows: six trials did not report on ethnic groups (<a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a>; <a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a>; <a href="./references#CD012436-bbs2-0014" title="OzkanB , BereketA , TuranS , KeskinS . Addition of orlistat to conventional treatment in adolescents with severe obesity. European Journal of Pediatrics2004;163(12):738‐41. ">Ozkan 2004</a>; <a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a>; <a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a>; <a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a>); one trial reported all their participants were white (<a href="./references#CD012436-bbs2-0005" title="ClarsonCL , MahmudFH , BakerJE , ClarkHE , MckayWM , SchauteetVD , et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine2009;36(1):141‐6. [DOI: 10.1007/s12020‐009‐9196‐9] ">Clarson 2009</a>), three trials reported approximately 75% of their population were white (<a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>; <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>); five trials reported approximately half of their population were white (<a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>; <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>); one trial reported that approximately 60% of their population were Hispanic (<a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>); one trial reported approximately 50% of their population were non‐Hispanic (<a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>); 63% of participants in one trial were non‐Hispanic black people while the remaining were non‐Hispanic white people (<a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>); and one trial reported that 64% of their participants came from ethnic backgrounds with a high prevalence of insulin resistance and metabolic syndrome (<a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a>). Participants' sex was not distributed evenly in 11 trials (<a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>; <a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>; <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a>; <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>; <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>; <a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a>; <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>). Three trials reported glycosylated haemoglobin A1c (HbA1c) at baseline and the mean HbA1c ranged from 5.3% to 5.6% (<a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>; <a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>). The mean BMI at baseline for the interventions groups ranged from 26.5 kg/m<sup>2</sup> to 41.5 kg/m<sup>2</sup>. The BMI at baseline for the comparator groups ranged from 26.2 kg/m<sup>2</sup> to 41.7 kg/m<sup>2</sup>. Thirteen trials reported comorbidities of participants at baseline (<a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a>; <a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>; <a href="./references#CD012436-bbs2-0005" title="ClarsonCL , MahmudFH , BakerJE , ClarkHE , MckayWM , SchauteetVD , et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine2009;36(1):141‐6. [DOI: 10.1007/s12020‐009‐9196‐9] ">Clarson 2009</a>; <a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>; <a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>; <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a>; <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>; <a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a>; <a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a>; <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>), all but one trial (<a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>) reported cointerventions in participants, and four trials had comedications used by participants (<a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>; <a href="./references#CD012436-bbs2-0014" title="OzkanB , BereketA , TuranS , KeskinS . Addition of orlistat to conventional treatment in adolescents with severe obesity. European Journal of Pediatrics2004;163(12):738‐41. ">Ozkan 2004</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>). Criteria for entry into the individual trials are outlined in the <a href="./references#CD012436-sec-0149" title="">Characteristics of included studies</a> table. Major trial exclusion criteria were major illnesses such as type 1 or 2 diabetes mellitus or cardiovascular disease; pregnancy; major psychiatric disorders; taking or previously taken medication known to influence body composition or contradiction to the drug therapy; cigarette smoking or alcohol use; obesity associated with genetic disorders; and eating disorders such as bulimia. Adherence/compliance with the intervention was reported in most trials as good (70% or more) and was usually assessed by pill counts. </p> </section> <section id="CD012436-sec-0084"> <h5 class="title">Diagnosis</h5> <p>All trials included participants who were defined as obese at baseline according to the growth reference they used, apart from one trial (<a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>), which also included overweight children in their inclusion criteria. Seven trials define obesity using the 95th percentile or greater cut‐off on the Centers for Disease Control and Prevention (CDC; <a href="./references#CD012436-bbs2-0225" title="KuczmarskiRJ , OgdenCL , Grummer‐StrawnLM , FlegalKM , GuoSS , WeiR , et al. CDC growth charts: United States. Advance Data2000;314:1‐27. ">Kuczmarski 2000</a>) charts (<a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a>; <a href="./references#CD012436-bbs2-0005" title="ClarsonCL , MahmudFH , BakerJE , ClarkHE , MckayWM , SchauteetVD , et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine2009;36(1):141‐6. [DOI: 10.1007/s12020‐009‐9196‐9] ">Clarson 2009</a>; <a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>; <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a>; <a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>), but <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a> also required their participants to weigh less than 136 kg. One trial used greater than 85th percentile (to include also overweight participants) (<a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>), while <a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a> used the 97th percentile or greater but also further selected for triceps skinfold thickness 97th percentile or greater for age and sex. <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a> defined obesity by BMI for age and triceps skinfold above the 95th percentile (determined by National Health and Nutrition Examination Survey (NHANES) I age‐, sex‐ and race‐specific data) and all participants were required to be over 60 kg in bodyweight. Alternatively two trials used the definition of obesity given by <a href="./references#CD012436-bbs2-0255" title="RosnerB , PrineasR , LoggieJ , DanielsSR . Percentiles for body mass index in U.S. children 5 to 17 years of age. Journal of Pediatrics1998;132:211‐22. ">Rosner 1998</a> of two units more than the US weighted mean of the 95th percentile but no greater than 44 kg/m<sup>2</sup> (<a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>). One trial used the IOTF (<a href="./references#CD012436-bbs2-0186" title="ColeTJ , BellizziMC , FlegalKM , DietzWH . Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ2000;320:1240‐53. ">Cole 2000</a>) definitions for obesity (<a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a>), while another used the WHO (<a href="./references#CD012436-bbs2-0270" title="World Health Organization. The Use and Interpretation of Antropometry. Geneva: WHO1995. ">WHO 1995</a>) growth standards cut‐off (<a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a>). <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a> used the UK BMI growth charts (<a href="./references#CD012436-bbs2-0185" title="ColeTJ , FreemanJV , PreeceMA . Body mass index reference curves for the UK, 1990. Archives of Disease in Childhood1995;73:25‐9. ">Cole 1995</a>), and used the 98th centile as the cut‐off for obesity. One trial used German references (<a href="./references#CD012436-bbs2-0224" title="Kromeyer‐HausschildK , WabitschM , KunzeD . Perzentile fur den Body‐mass‐Index fűr das Kindes‐und Jugendalterunter Heranziehung verschiedener deutscher Stichproben. Monatsschr Kinderheilkd2001;149:807‐18. [DOI: 10.1007/s001120170107] ">Kromeyer‐Hausschild 2001</a>) to define obesity using greater than 97th percentile (<a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>). Three trials used raw BMI to define obesity: BMI greater than 30 kg/m<sup>2</sup> (<a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>); BMI 32 kg/m<sup>2</sup> to 44 kg/m<sup>2</sup> (<a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>); and BMI 30 kg/m<sup>2</sup> to 45 kg/m² (<a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a>). In two trials, it was unclear which growth reference charts they were referring to (<a href="./references#CD012436-bbs2-0014" title="OzkanB , BereketA , TuranS , KeskinS . Addition of orlistat to conventional treatment in adolescents with severe obesity. European Journal of Pediatrics2004;163(12):738‐41. ">Ozkan 2004</a>; <a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a>). Participants were diagnosed with type 1 or 2 diabetes mellitus in none of our included trials. However, some trials included additional inclusion criteria other than age and obesity: <a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a> required all participants to have hyperinsulinaemia; <a href="./references#CD012436-bbs2-0005" title="ClarsonCL , MahmudFH , BakerJE , ClarkHE , MckayWM , SchauteetVD , et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine2009;36(1):141‐6. [DOI: 10.1007/s12020‐009‐9196‐9] ">Clarson 2009</a> only included participants who were insulin resistant (defined by homeostasis model assessment (HOMA) for insulin resistance values greater than 3); <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a> required all participants to have an adult bone age determined by left hand radiography (Greulich‐Pyle method); <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a> only included participants who had impaired glucose tolerance or hyperinsulinaemia; <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a> only recruited participants who had comorbidities at baseline and these included hypertension, hyperinsulinaemia and hepatic steatosis; <a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a> only included participants where there was a suspicion of insulin resistance (fasting insulin to glucose ratio greater than 4.5 or presence of acanthosis nigricans); <a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a> required all participants to present with at least one risk factor for type 2 diabetes (e.g. first‐ or second‐degree relative with history of type 2 diabetes); <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a> only included participants who had normal glucose tolerance but also had elevated highly sensitive C‐reactive protein (hsCRP), fibrinogen concentrations or both; <a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a> inclusion criteria included a fasting insulin concentration exceeding 15 IU/mL and at least one first‐ or second‐degree relative with type 2 diabetes; and <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a> required all participants to have hyperinsulinaemia (defined as fasting insulin 15 IU/mL or greater). All participants in <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a> presented with comorbidities at baseline (features of the metabolic syndrome); however, this did not appear to be an inclusion criterion. </p> </section> <section id="CD012436-sec-0085"> <h5 class="title">Interventions</h5> <p>Eleven trials used metformin as their pharmacological intervention (<a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a>; <a href="./references#CD012436-bbs2-0005" title="ClarsonCL , MahmudFH , BakerJE , ClarkHE , MckayWM , SchauteetVD , et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine2009;36(1):141‐6. [DOI: 10.1007/s12020‐009‐9196‐9] ">Clarson 2009</a>; <a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>; <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a>; <a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a>; <a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a>; <a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a>; <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>). The intervention was administered orally and varied between one and four times per day. Between trials, the daily dosage of metformin varied between 500 mg and 2000 mg, with a mean daily dosage of 1364 mg. Four metformin trials reported treatment before the start of the trial (<a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a>; <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>); this included a healthy 'lifestyle' advice sheet, lifestyle modification treatment and a six‐month multiprofessional lifestyle intervention. Seven trials had a titration period, consisting of increasing the number of tablets taken over a period of weeks until the maximum dosage was tolerated (<a href="./references#CD012436-bbs2-0005" title="ClarsonCL , MahmudFH , BakerJE , ClarkHE , MckayWM , SchauteetVD , et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine2009;36(1):141‐6. [DOI: 10.1007/s12020‐009‐9196‐9] ">Clarson 2009</a>; <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a>; <a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a>; <a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>). Two trials did not have a matching placebo in the comparator group ‐ participants received a lifestyle intervention only (<a href="./references#CD012436-bbs2-0005" title="ClarsonCL , MahmudFH , BakerJE , ClarkHE , MckayWM , SchauteetVD , et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine2009;36(1):141‐6. [DOI: 10.1007/s12020‐009‐9196‐9] ">Clarson 2009</a>; <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a>). The duration of treatment ranged from 12 weeks/three months to six months with a mean treatment duration of 5.5 months. </p> <p>Six trials used sibutramine as their intervention (<a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a>; <a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>; <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a>; <a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a>). In all six trials, the drug was administered orally once daily. The daily dosage of sibutramine varied between 5 mg and 15 mg, with a mean daily dose of 11 mg. Three trials reported that participants received treatment before the start of the trial (<a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a>; <a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>; <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a>); this included dietetic advice/counselling and a six‐month lifestyle intervention. Two trials had a titration period (<a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a>). All trials had a matching placebo as the comparator intervention. The duration of treatment ranged from 12 weeks to 12 months, with a mean treatment duration of 6.5 months. </p> <p>Four trials gave orlistat to their intervention group (<a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>; <a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>; <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>; <a href="./references#CD012436-bbs2-0014" title="OzkanB , BereketA , TuranS , KeskinS . Addition of orlistat to conventional treatment in adolescents with severe obesity. European Journal of Pediatrics2004;163(12):738‐41. ">Ozkan 2004</a>). The drug was administered orally three times per day and the daily dosage of orlistat was 360 mg in all four trials. No trials gave participants any treatment before the trial. One trial did not give a matching placebo to the comparator group ‐ participants received a lifestyle intervention only (<a href="./references#CD012436-bbs2-0014" title="OzkanB , BereketA , TuranS , KeskinS . Addition of orlistat to conventional treatment in adolescents with severe obesity. European Journal of Pediatrics2004;163(12):738‐41. ">Ozkan 2004</a>). The duration of treatment ranged from six months to 12 months, with a mean treatment duration of 8.9 months. </p> <p>One trial also included two additional intervention arms: metformin plus fluoxetine and fluoxetine only (<a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a>). The drugs were given by the oral route once daily. The daily dose of fluoxetine was 20 mg. Participants were also given lifestyle modification treatment before the start of the trial. They also had a titration period. The comparator group received a matching placebo. The duration of treatment was 12 weeks. </p> </section> <section id="CD012436-sec-0086"> <h5 class="title">Outcomes</h5> <p>Fourteen trials explicitly stated a primary endpoint in the publication (<a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>; <a href="./references#CD012436-bbs2-0005" title="ClarsonCL , MahmudFH , BakerJE , ClarkHE , MckayWM , SchauteetVD , et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine2009;36(1):141‐6. [DOI: 10.1007/s12020‐009‐9196‐9] ">Clarson 2009</a>; <a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>; <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a>; <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>; <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a>; <a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a>; <a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a>; <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>), 10 trials reported 'secondary' endpoints (<a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>; <a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>; <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a>; <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>; <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>). <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a> had no publication attached; however, the trial authors reported both a primary and secondary endpoint on the clinical trials website. The most commonly defined primary outcomes in publications were change in absolute BMI, change in BMI z score/standard deviation score (SDS) and change in bodyweight. The most commonly defined primary outcomes in trial protocols were change in BMI from baseline and per cent change in BMI. </p> </section> <section id="CD012436-sec-0087"> <h5 class="title">Reporting of endpoints</h5> <p>Twenty‐one trials collected a mean of 14 (range four to 25) outcomes. All 21 trials measured raw BMI. Ten trials reported change in BMI z score/SDS (<a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0005" title="ClarsonCL , MahmudFH , BakerJE , ClarkHE , MckayWM , SchauteetVD , et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine2009;36(1):141‐6. [DOI: 10.1007/s12020‐009‐9196‐9] ">Clarson 2009</a>; <a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>; <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>; <a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a>; <a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a>; <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>). All 21 trials reported on whether adverse events occurred. Of those trials which reported adverse events, some reported the total number of adverse events whilst others reported the total number of participants who experienced at least one adverse event. We asked all authors to provide further details on adverse events, such as how many participants experienced severe adverse events and if so, whether they were hospitalised. Two trials measured health‐related quality of life with validated questionnaires (<a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>; <a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>). Seventeen trials reported that they measured body fat distribution. Fifteen trials measured waist circumference, hip circumference, or both (<a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>; <a href="./references#CD012436-bbs2-0005" title="ClarsonCL , MahmudFH , BakerJE , ClarkHE , MckayWM , SchauteetVD , et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine2009;36(1):141‐6. [DOI: 10.1007/s12020‐009‐9196‐9] ">Clarson 2009</a>; <a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a>; <a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>; <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a>; <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a>; <a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a>; <a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a>; <a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a>; <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>). Seven trials measured body fat mass by DEXA (<a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>; <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a>; <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>; <a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a>; <a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>). Two trials also measured body fat mass by bioelectrical impedance (<a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>; <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>). Six trials measured behaviour change (<a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a>; <a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>; <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>; <a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a>). Five trials measured food consumption through dietary records or questionnaires (<a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a>; <a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>; <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>; <a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a>), and one trial measured the feeling of hunger (<a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>). Two trials measure changes in physical activity: <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a> used a physical activity questionnaire and <a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a> measured total energy expenditure which accounts for level of physical activity. Only one trial investigated morbidity defined as illness or harm associated with the intervention (<a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>). One trial reported a death from suicide (<a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>). <a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a> reported two suicide attempts which did not result in death. </p> <p>No trials assessed participants' views or socioeconomic effects as outcomes. For a summary of all outcomes assessed in each trial, see <a href="./appendices#CD012436-sec-0129">Appendix 5</a>. </p> </section> </section> <section id="CD012436-sec-0088"> <h4 class="title">Excluded studies</h4> <p>We excluded 135 trials or trial records after careful evaluation of the full publication. The main reasons for exclusion were the participants were adults or had a mean age of more than 18 years, the trial design was not an RCT, the duration of treatment was less than three months or the duration of follow‐up was less than six months. For further details, see <a href="./references#CD012436-sec-0150" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD012436-sec-0089"> <h3 class="title">Risk of bias in included studies</h3> <p>For details on risk of bias of included trials see <a href="./references#CD012436-sec-0149" title="">Characteristics of included studies</a> table. For an overview of review authors' judgements about each risk of bias item for individual trials and across all trials, see <a href="#CD012436-fig-0002">Figure 2</a> and <a href="#CD012436-fig-0003">Figure 3</a>. We investigated performance bias, detection bias and attrition bias separately for objective and subjective outcome measures. </p> <div class="figure" id="CD012436-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials." data-id="CD012436-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials. </p> </div> </div> </div> <div class="figure" id="CD012436-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial." data-id="CD012436-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial. </p> </div> </div> </div> <section id="CD012436-sec-0090"> <h4 class="title">Allocation</h4> <p>Fifteen trials reported allocation was concealed (<a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>; <a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a>;<a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>; <a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>; <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a>; <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a>; <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>; <a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a>; <a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a>; <a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a>; <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>); two trials did not conceal allocation (<a href="./references#CD012436-bbs2-0005" title="ClarsonCL , MahmudFH , BakerJE , ClarkHE , MckayWM , SchauteetVD , et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine2009;36(1):141‐6. [DOI: 10.1007/s12020‐009‐9196‐9] ">Clarson 2009</a>; <a href="./references#CD012436-bbs2-0014" title="OzkanB , BereketA , TuranS , KeskinS . Addition of orlistat to conventional treatment in adolescents with severe obesity. European Journal of Pediatrics2004;163(12):738‐41. ">Ozkan 2004</a>). It was unclear whether four trials concealed allocation (<a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a>; <a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a>;<a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>) ). Fourteen trials reported an adequate random sequence generation (<a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>; <a href="./references#CD012436-bbs2-0005" title="ClarsonCL , MahmudFH , BakerJE , ClarkHE , MckayWM , SchauteetVD , et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine2009;36(1):141‐6. [DOI: 10.1007/s12020‐009‐9196‐9] ">Clarson 2009</a>; <a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a>; <a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>; <a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>; <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a>; <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>; <a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a>; <a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a>; <a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>). Two trials reported random sequence generation was inadequate; hence, would have likely of introduced bias (<a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>; <a href="./references#CD012436-bbs2-0014" title="OzkanB , BereketA , TuranS , KeskinS . Addition of orlistat to conventional treatment in adolescents with severe obesity. European Journal of Pediatrics2004;163(12):738‐41. ">Ozkan 2004</a>).Five trials did not describe the randomisation process (<a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a>; <a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a>; <a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a>; <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>). </p> </section> <section id="CD012436-sec-0091"> <h4 class="title">Blinding</h4> <p>All 21 trials reported both objective and subjective outcomes. The main objectives outcomes were BMI, weight, waist or hip circumference, blood pressure, cholesterol insulin, glucose and triglycerides, whilst the main subjective outcomes were adverse events, food consumption and health‐related quality of life. Subjective outcomes tended to be self‐reported (e.g. quality of life and dietary questionnaires), while objective measures usually were investigator‐assessed (e.g. BMI, waist circumference). Adverse events could be either self‐reported or investigator assessed. </p> <p>Ten trials explicitly stated that blinding of the participants, personnel and outcome assessors was undertaken (<a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a>; <a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>; <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>; <a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a>; <a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a>; <a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>). Seven trials reported that double blinding took place (<a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a>; <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>; <a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>; <a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>; <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a>; <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>), but only three of the trials' authors confirmed this meant blinding was undertaken of participants, personnel and outcomes assessors (<a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>; <a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>; <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a>). No trials reported that single blinding was undertaken. Six trials did not provide sufficient information about blinding procedures (<a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a>; <a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>; <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0014" title="OzkanB , BereketA , TuranS , KeskinS . Addition of orlistat to conventional treatment in adolescents with severe obesity. European Journal of Pediatrics2004;163(12):738‐41. ">Ozkan 2004</a>; <a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a>; <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>). </p> </section> <section id="CD012436-sec-0092"> <h4 class="title">Incomplete outcome data</h4> <p>Twenty trials that had losses to follow‐up described the number of trial withdrawals (<a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>; <a href="./references#CD012436-bbs2-0005" title="ClarsonCL , MahmudFH , BakerJE , ClarkHE , MckayWM , SchauteetVD , et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine2009;36(1):141‐6. [DOI: 10.1007/s12020‐009‐9196‐9] ">Clarson 2009</a>; <a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a>; <a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>; <a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>; <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a>; <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>; <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a>; <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>; <a href="./references#CD012436-bbs2-0014" title="OzkanB , BereketA , TuranS , KeskinS . Addition of orlistat to conventional treatment in adolescents with severe obesity. European Journal of Pediatrics2004;163(12):738‐41. ">Ozkan 2004</a>; <a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a>; <a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a>; <a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a>; <a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a>; <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>). Twelve trials used ITT analyses (<a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>; <a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>; <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a>; <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>; <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>; <a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a>; <a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>). One trial did not report whether there were any losses to follow‐up (<a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a>). Five trials did not provide detailed descriptions of participants' withdrawals and reasons underpinning them (<a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a>; <a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a>; <a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>; <a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>; <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a>). Four trials had attrition rates greater than 30% with possible impact on the outcomes(<a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>; <a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a>; <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a>; <a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a>;<a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>). </p> </section> <section id="CD012436-sec-0093"> <h4 class="title">Selective reporting</h4> <p>Only nine trials provided a clinical trial identifier or reference to a protocol <i>(</i><a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a>; <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>; <a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a>; <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>); however, we were unable to source the clinical trial entry of one trial (<a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>). Three trials had a high risk of reporting bias after failure to report results for one or more outcomes they described as having measured <i>(</i><a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a>; <a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>; <a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>), and a further trial had a high risk due to differences in results reported on the clinical trial website and in a conference abstract (<a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>). The remaining trials had unclear risk of reporting bias due to no protocol being available. </p> </section> <section id="CD012436-sec-0094"> <h4 class="title">Other potential sources of bias</h4> <p>Seven trials were at high risk of other biases. These biases included: the trial not including a power calculation (<a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a>; <a href="./references#CD012436-bbs2-0005" title="ClarsonCL , MahmudFH , BakerJE , ClarkHE , MckayWM , SchauteetVD , et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine2009;36(1):141‐6. [DOI: 10.1007/s12020‐009‐9196‐9] ">Clarson 2009</a>; <a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a>; <a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>; <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a>; <a href="./references#CD012436-bbs2-0014" title="OzkanB , BereketA , TuranS , KeskinS . Addition of orlistat to conventional treatment in adolescents with severe obesity. European Journal of Pediatrics2004;163(12):738‐41. ">Ozkan 2004</a>), the trial lacking methodological detail (<a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a>; <a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a>) and the trial not adjusting for baseline differences (<a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>; <a href="./references#CD012436-bbs2-0014" title="OzkanB , BereketA , TuranS , KeskinS . Addition of orlistat to conventional treatment in adolescents with severe obesity. European Journal of Pediatrics2004;163(12):738‐41. ">Ozkan 2004</a>), The remaining 14 trials were at unclear risk of other potential sources of bias. It is important to note that the trials which do not include a power calculation may not be powered to detect differences in their primary outcome. BMI or weight was the primary outcome in all but two trials (<a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a>; <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>) that included a power calculation. <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a> and <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a> may not have been adequately powered to detect differences in BMI or weight. With regards to adverse events and the review's secondary outcomes (e.g. morbidity), it is likely that most trials would not have been powered to detect differences in these outcomes. Hence, these results should be interpreted with caution. </p> </section> </section> <section id="CD012436-sec-0095"> <h3 class="title" id="CD012436-sec-0095">Effects of interventions</h3> <p>See: <a href="./full#CD012436-tbl-0001"><b>Summary of findings for the main comparison</b> Drug interventions for the treatment of obesity in children and adolescents</a> </p> <section id="CD012436-sec-0096"> <h4 class="title">Baseline characteristics</h4> <p>For details of baseline characteristics, see <a href="./appendices#CD012436-sec-0127">Appendix 3</a> and <a href="./appendices#CD012436-sec-0128">Appendix 4</a>. </p> </section> <section id="CD012436-sec-0097"> <h4 class="title">Pharmacological intervention versus comparators</h4> <p>We performed the meta‐analyses with CMA software version 3 and aligned with the data in the Review Manager 5 (<a href="./references#CD012436-bbs2-0252" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) meta‐analyses. Because the cross‐over design did not appear suitable for our research question due to inadequate washout periods and noncomparable baseline measures in the two cross‐over periods, we excluded <a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a> and <a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a> from all meta‐analyses. We also excluded <a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a> from the meta‐analyses because the reported SDs were unreliably small in comparison to all other published SDs of included trials and probably denoted standard errors. We excluded two further trials because of substantial methodological concerns (<a href="./references#CD012436-bbs2-0014" title="OzkanB , BereketA , TuranS , KeskinS . Addition of orlistat to conventional treatment in adolescents with severe obesity. European Journal of Pediatrics2004;163(12):738‐41. ">Ozkan 2004</a>; <a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a>). In addition, <a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a> did not report change in BMI from baseline to follow‐up and <a href="./references#CD012436-bbs2-0014" title="OzkanB , BereketA , TuranS , KeskinS . Addition of orlistat to conventional treatment in adolescents with severe obesity. European Journal of Pediatrics2004;163(12):738‐41. ">Ozkan 2004</a> did not have a consistent follow‐up time frame across all participants. </p> <section id="CD012436-sec-0098"> <h5 class="title">Primary outcomes</h5> <section id="CD012436-sec-0099"> <h6 class="title">Body mass index and bodyweight</h6> <p>We included 16 trials in the meta‐analysis of BMI. Most of the BMI data were from the publications, except for <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a> and <a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>, where raw BMI, SDs or both were not available; hence, we obtained additional data from the trial authors. We extracted data for <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a> from the ClinicalTrials.gov website. In the meta‐analysis, we included trials which had either a six‐month or 12‐month follow‐up from baseline (<a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>), which was the endpoint in most of the trials. However, even though <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a> had a 12‐month follow‐up, we only had data available at six months from baseline. <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a> provided data at 100 weeks' follow‐up but we did not include these in the meta‐analysis. </p> <p>The summary estimate across all pharmacological interventions versus all comparators (metformin, orlistat or sibutramine mostly versus placebo ‐ usually combined with behaviour changing interventions) showed a MD in BMI change of ‐1.3 kg/m<sup>2</sup> (95% CI ‐1.9 to ‐0.8; P &lt; 0.00001; 16 trials; 1884 participants; low certainty evidence ‐ <a href="./references#CD012436-fig-0006" title="">Analysis 1.1</a>) in favour of the drug interventions. Heterogeneity was considerable (I<sup>2</sup> = 77%). </p> <p>In <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>, which reported a BMI change at 100 weeks from baseline (48 weeks of metformin or placebo treatment, then a 48‐week drug‐free period), the metformin group increased their BMI during the drug‐free period (+0.5) while the placebo group decreased their BMI (‐0.8), measured as the difference between 52 and 100 weeks from baseline. In the metformin plus fluoxetine trial, the fluoxetine only group had a decrease in BMI of ‐0.6 (SD 0.1) and the metformin plus fluoxetine group had a decrease in BMI of ‐0.9 (SD 0.02), compared to an increase of 0.2 (SD 0.04) in the placebo group at 24 weeks from baseline. </p> <p>Only 11 trials reported weight data at baseline or follow‐up (or change from baseline) in their publications; hence, we only included these trials in the meta‐analysis. Data were reported at six months from baseline apart from one trial (<a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>), which reported the change in weight at 12 months from baseline. The summary estimate across all pharmacological interventions versus comparators (metformin, orlistat or sibutramine mostly versus placebo ‐ usually combined with behaviour changing interventions) showed an MD in change in weight of ‐3.9 kg (95% CI ‐5.9 to ‐1.9; P &lt; 0.00001; 11 trials; 1180 participants; low certainty evidence ‐ <a href="./references#CD012436-fig-0015" title="">Analysis 2.1</a>) in favour of the drug interventions. Heterogeneity was considerable (I<sup>2</sup> = 79%). </p> </section> <section id="CD012436-sec-0100"> <h6 class="title">Adverse events</h6> <p>Only three trials had sufficiently long exposure times to evaluate adverse events possibly associated with drug interventions for obesity in children and adolescents: one trial with 39 participants randomised to metformin treatment for 100 weeks (<a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>), one trial with 368 participants randomised to sibutramine treatment for 12 months (<a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>), and one trial with 357 participants randomised to orlistat treatment for 54 weeks (<a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>). </p> <p>Adverse events were reported to have occurred in all 11 metformin trials except from <a href="./references#CD012436-bbs2-0005" title="ClarsonCL , MahmudFH , BakerJE , ClarkHE , MckayWM , SchauteetVD , et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine2009;36(1):141‐6. [DOI: 10.1007/s12020‐009‐9196‐9] ">Clarson 2009</a>, which reported that metformin was well tolerated, and the author clarified no adverse events occurred. Gastrointestinal adverse events were most commonly reported with one metformin trial reporting that gastrointestinal adverse events were statistically more prevalent in the intervention group compared to the control group (<a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>). However, <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a> reported such events occurred more frequently in the placebo group. <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a> reported adverse events were more common in the metformin group and were mainly gastrointestinal. <a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a> reported that two metformin‐treated participants experienced diarrhoea, mild abdominal pain/discomfort, or both. <a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a> also reported three participants experienced transient abdominal discomfort or diarrhoea, however so did one placebo participant. <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a> reported that the most common adverse events included headache, nausea, vomiting, upper respiratory tract infection and musculoskeletal complaints; however, none were statistically different between the metformin and placebo groups. One trial showed the fatigue was more common in the metformin‐treated children (<a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>). Furthermore, <a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a> reported one case of an exacerbation of migraine and one case of transient nausea in the metformin arm. Nausea was reported in the <a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a> trial where two participants were unable to tolerate a higher dose of metformin (1 g); however, they tolerated a lower dose and continued in the trial. <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a> also reported that levels of serum vitamin B<sub>12</sub> were reduced in the metformin group compared with an increase in the placebo group ‐ this difference was statistically significant. <a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a> reported two cases of headache, two cases of abdominal pain and three cases of loose stools in the metformin arm but they were all minor and tolerable. <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a> reported metformin was well tolerated and safe, and the author added that the adverse effects between groups were comparable. <a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a> reported metformin was well tolerated by participants and both groups showed a significant increase in alanine transaminase (ALT) and aspartate transaminase (AST), and a reduction in haemoglobin levels, but these were within the normal ranges. </p> <p>Three of six trials on sibutramine therapy reported on adverse events: one large trial showed tachycardia, dry mouth, constipation, dizziness, insomnia and hypertension were all reported more frequently by sibutramine participants than by placebo participants (<a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>). Sibutramine‐treated participants also had a higher blood pressure and pulse rate at 12 months' follow‐up compared to the placebo‐treated participants (<a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>). However, another trial reported that there was no statistically significant difference between changes in heart rate or blood pressure between the sibutramine and placebo groups, although abdominal cramps were significantly higher in the sibutramine group (<a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a>). <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a> showed constipation was significantly higher in the sibutramine group compared to the placebo group. </p> <p>All four orlistat trials reported on adverse events: gastrointestinal problems such as fatty stools, oily spotting and fecal urgency, along with headaches and upper respiratory tract infections, were the most common adverse effects. In the <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a> trial, the prevalence of some gastrointestinal problems was higher in the orlistat group compared to the placebo group and this included: fatty‐appearing stools, bloating/gas, frequent urge for bowel movement and uncontrolled passage of stool or oil. <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a> reported that gastrointestinal tract‐related adverse events were more common in the orlistat group compared to the placebo group; however, most were classed as mild to moderate intensity. <a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a> also reported that the orlistat group had significantly increased gastrointestinal adverse events (e.g. soft stools, oily spotting) compared to the placebo group. Mild gastrointestinal complaints (frequent stools) were experienced by all orlistat‐receiving participants in the <a href="./references#CD012436-bbs2-0014" title="OzkanB , BereketA , TuranS , KeskinS . Addition of orlistat to conventional treatment in adolescents with severe obesity. European Journal of Pediatrics2004;163(12):738‐41. ">Ozkan 2004</a> trial. <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a> also reported that 10 orlistat and one placebo participant showed abnormalities detected on electrocardiograms; however, an independent cardiologist concluded that none were connected to the treatment; in addition, levels of oestradiol in girls decreased in the orlistat group versus a slight increase in the placebo group (P = 0.05). Symptomatic gallstones were also seen in six orlistat participants which were not seen at baseline (five of these participants had lost large amounts of weight). </p> <p>In the trial which included a fluoxetine arm, there were five adverse events with regards to the drug which included three cases of dry mouth and two cases of loose stool; these were all considered as minor and tolerable, and reported as transient (<a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a>). </p> <p>Serious/severe adverse events were also investigated: most trials did not report how they defined a serious/severe adverse event. It was also unclear in four trials whether a serious/severe adverse event actually occurred (<a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0014" title="OzkanB , BereketA , TuranS , KeskinS . Addition of orlistat to conventional treatment in adolescents with severe obesity. European Journal of Pediatrics2004;163(12):738‐41. ">Ozkan 2004</a>; <a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a>; <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>). Only five trials reported that a serious or severe adverse event occurred (<a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>; <a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>; <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>); the remaining 12 trials reported that there were no serious or severe adverse events. </p> <p>Across all trials the RR for serious adverse events comparing drug interventions with comparators was 1.43 (95% CI 0.63 to 3.25; P = 0.39; 5 trials; 1347 participants; low certainty evidence ‐ <a href="./references#CD012436-fig-0017" title="">Analysis 3.1</a>). Absolute numbers experiencing a serious adverse event were 24/878 (2.7%) participants in the drug intervention groups versus 8/469 (1.7%) participants in the comparator groups. </p> <p>In the metformin trials, only one trial reported that there were serious adverse events and these included one case of appendectomy and one case of leg vein thrombosis in the metformin group, but these were both seen as unrelated to the drug (<a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>). One sibutramine trial reported that 2.7% of sibutramine‐treated participants experienced serious adverse events which included one case of excessive nausea and vomiting, one suicide attempt and five depression cases (<a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>). The placebo group had one case of suicide attempt and one case of depression. <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a> reported 3% of participants experienced at least one serious adverse event: the five events in the placebo group included acute demyelinating encephalomyelitis, facial palsy, pneumonia, worsening of asthma and pain in the right side; and the 11 events in the orlistat group included pilonidal abscess, depression, asthma attack, seizure, admission for repair of deviated nasal septum, appendicitis, cholelithiasis, gallbladder disorder followed by cholecystectomy, adenoidal hypertrophy and aseptic meningitis. It was only the case of cholelithiasis in the orlistat participant which was seen to be possibly related to the trial medication potentially due to rapid weight loss. Another orlistat trial reported two serious adverse events in the placebo group and these were one case of hypoglycaemia and one case of left lower quadrant pain and vomiting (<a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a>). </p> <p>In the sibutramine trials, 32 participants (24 in the intervention groups and eight in the control groups) left the trial because of adverse events. <a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a> reported that withdrawals due to tachycardia were similar in both groups but hypertension led to the withdrawal of five participants in the sibutramine group versus none in the placebo group. Two cases of attempted suicide (one intervention and one placebo) also led to discontinuation but were considered unlikely to be related to the trial drug; one case of excessive nausea and vomiting in the sibutramine group also led to withdrawal and may have been related to the drug. <a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a> had one withdrawal from the sibutramine group due to symptoms of clinical depression and <a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a> had one withdrawal from the placebo group. </p> <p>In the metformin trials, nine participants withdrew due to adverse events (five in intervention group and four in placebo group). <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a> reported one participant from the metformin group withdrew due to nausea which was probably related to the drug, and a further two metformin and one placebo participants dropped out of the trial due to elevated levels of ALT. Gastrointestinal symptoms caused 6% of participants (one in metformin group and three in placebo group) to drop out of the <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a> trial. In addition, <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a> reported one participant dropped out of the metformin group due to medication intolerance. </p> <p>Across all trials the RR for discontinuing the trial because of adverse events comparing drug interventions with comparators was 1.45 (95% CI 0.83 to 2.52; P = 0.19; 10 trials; 1664 participants; low certainty evidence ‐ <a href="./references#CD012436-fig-0018" title="">Analysis 3.2</a>). Absolute numbers discontinuing the trial because of an adverse event were 52/1043 (5.0%) participants in the drug intervention groups versus 17/621 (2.7%) participants in the comparator groups. </p> <p>All four orlistat trials had dropouts due to adverse events; 28 participants (23 in the intervention group and five in the placebo group). <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a> reported 12 dropouts (3%) in the orlistat group and three dropouts (2%) in the placebo group, mainly due to gastrointestinal adverse events. <a href="./references#CD012436-bbs2-0014" title="OzkanB , BereketA , TuranS , KeskinS . Addition of orlistat to conventional treatment in adolescents with severe obesity. European Journal of Pediatrics2004;163(12):738‐41. ">Ozkan 2004</a> reported seven participants (32%) dropped out of the orlistat group due to gastrointestinal complaints. <a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a> reported two participants in the orlistat group discontinued due to adverse events (assumed to be gastrointestinal) and one participant in the orlistat group committed suicide. <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a> reported one participant in the orlistat group and two participants in the placebo group dropped out of the trial due to medication intolerance. </p> <p>For further details, see <a href="./appendices#CD012436-sec-0133">Appendix 9</a>, <a href="./appendices#CD012436-sec-0134">Appendix 10</a>, and <a href="./appendices#CD012436-sec-0135">Appendix 11</a>. </p> </section> </section> <section id="CD012436-sec-0101"> <h5 class="title">Secondary outcomes</h5> <section id="CD012436-sec-0102"> <h6 class="title">Health‐related quality of life</h6> <p>Two trials measured health‐related quality of life; the certainty of the evidence was very low. <a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a> used the 36‐Item Short‐Form Health Survey (SF‐36) questionnaire and found changes in the total score were slightly higher in the sibutramine group compared to the placebo group, but this difference was not statistically significant. <a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a> used three questionnaires to assess health‐related quality of life, but found no statistically significant differences between the orlistat and placebo group from baseline to six months. For further details on the health‐related quality of life measurements, see <a href="./appendices#CD012436-sec-0138">Appendix 14</a>. </p> </section> <section id="CD012436-sec-0103"> <h6 class="title">Body fat distribution</h6> <p>Eighteen trials reported outcomes which measured body fat distribution. Fifteen of these trials measured waist, hip, or both circumferences at baseline and follow‐up. In the metformin trials, <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a> found greater decreases in waist circumference in the metformin plus diet plus exercise group compared with the diet plus exercise group at six months' follow‐up. However, this trial was not placebo controlled. In addition, <a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a>, a cross‐over trial, reported a beneficial treatment effect on waist circumference in participants taking metformin for six months, when compared to six months of placebo. However, there was no statistically significant difference in waist circumference between the drug and control groups in <a href="./references#CD012436-bbs2-0005" title="ClarsonCL , MahmudFH , BakerJE , ClarkHE , MckayWM , SchauteetVD , et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine2009;36(1):141‐6. [DOI: 10.1007/s12020‐009‐9196‐9] ">Clarson 2009</a> and <a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a> trials at six months' follow‐up. <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a> measured waist circumference but did not report results. Two metformin trials also measured waist‐to‐hip ratio and found no statistically significant difference between groups at six months' follow‐up (<a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>). <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a> also measured abdominal and hip circumference at six months' follow‐up, and found a statistically significant difference between metformin and placebo, in favour of the intervention. In the metformin plus fluoxetine trial, only the metformin plus fluoxetine arm had a statistically significant between‐group difference in waist circumference at 24 weeks from baseline (<a href="./references#CD012436-bbs2-0016" title="RezvanianH , HashemipourM , KelishadiR , TavakoliN , PoursafaP . A randomized, triple masked, placebo‐controlled clinical trial for controlling childhood obesity. World Journal of Pediatrics2010;6(4):317‐22. [DOI: 10.1007/s12519‐010‐0232‐x] ">Rezvanian 2010</a>). In the sibutramine trials, there was a statistically significant difference in waist circumference in favour of the intervention in five trials (<a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a>; <a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0006" title="FrancoRR , CominatoL , DamianiD . The effect of sibutramine on weight loss in obese adolescents [O efeito da sibutramina na perda de peso de adolescentes obesos]. Arquivos Brasileiros de Endocrinologia e Metabologia2014;58:243‐50. ">Franco 2014</a>; <a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>; <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a>). <a href="./references#CD012436-bbs2-0009" title="CorreaLL , PlattMW , CarraroL , MoreiraRO , JuniorRF , Godoy‐MatosAF , et al. Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents [Avaliação do efeito da sibutramina sobre a saciedade por escala visual analógica em adolescentes obesos]. Arquivos Brasileiros de Endocrinologia &amp; Metabologia2005;49(2):286‐90. Godoy‐MatosA , CarraroL , VieiraA , OliveiraJ , GuedesEP , MattosL , et al. Treatment of obese adolescents with sibutramine: a randomized, double‐blind, controlled study. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1460‐5. ">Godoy‐Matos 2005</a> also reported a statistically significant reduction in hip circumference in the sibutramine group compared to the placebo group; however, there was no statistically significant difference for waist‐to‐hip ratio at six months. Only one orlistat trial measured waist circumference and found it increased in the placebo group but decreased in the orlistat group at one year' follow‐up (difference statistically significant); this was also seen for hip circumference (<a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>). </p> <p>Seven trials measured body composition by DEXA. Four metformin trials and two orlistat trials measured body fat using DEXA. Three metformin trials found no statistically significant difference between groups in the percentage of body fat lost (<a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a>; <a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a>; <a href="./references#CD012436-bbs2-0020" title="WilsonDM , AbramsSH , AyeT , LeePD , LendersC , LustigRH , et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Archives of Pediatrics &amp; Adolescent Medicine2010;164(2):116‐23. [DOI: 10.1001/archpediatrics.2009.264] ">Wilson 2010</a>). However, one trial observed a statistically significant difference of 1.4 kg between the metformin and placebo groups, in favour of the intervention group at six months' follow‐up (<a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>). One sibutramine trial assessed body composition using underwater weighing and DEXA; however, there was no statistically significant difference in percentage of fat mass between groups. <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a> reported they measured fat mass by DEXA in a subgroup of participants as a safety measure and the orlistat group lost more fat mass compared to the placebo group (P = 0.03). <a href="./references#CD012436-bbs2-0013" title="CondarcoTA , Sherafat‐KazemzadehR , McDuffieJR , BradyS , SalaitaC , SebringNG , et al. Long‐term follow‐up of a randomized, placebo‐controlled trial of orlistat in African‐American and Caucasian adolescents with obesity‐related comorbid conditions. Endocrine Reviews2013. RadinRM , Tanofsky‐KraffM , ShomakerLB , KellyNR , PickworthCK , ShankLM , et al. Metabolic characteristics of youth with loss of control eating. Eating Behaviors2015;19:86‐9. ">NCT00001723</a> found a slightly greater decrease in body fat (kg) in the orlistat group compared to the placebo group. Two trials estimated fat mass from bioimpedence analysis: one orlistat trial (<a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>) and one metformin trial (<a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>), but they reported no statistically significant difference between intervention and placebo groups. <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a> measured fat mass by air displacement plethysmography and found metformin participants had statistically significant decreases in their fat mass compared to placebo participants; they also measured intra‐abdominal fat by magnetic resonance imaging but found no statistically significant difference between groups. <a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a> also used magnetic resonance imaging and found a beneficial treatment effect of metformin over placebo for subcutaneous abdominal adipose tissue but not visceral abdominal adipose tissue; <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a> also used this technique and found that intrahepatic fat only decreased in the nonplacebo control group. <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a> used abdominal computer tomography (CT) scans to evaluate abdominal fat content but also found no statistically significant difference between metformin and placebo participants in the results. </p> </section> <section id="CD012436-sec-0104"> <h6 class="title">Behaviour change</h6> <p>Six trials measured behaviour change; however, only two trials reported the results. Participants in three trials all completed a food frequency questionnaire at the beginning and end of the trial; however, no results were presented (<a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a>; <a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a>; <a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>). <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a> assessed dietary habits and exercise levels through three previously validated questionnaires but were unable to analyse the data due to insufficient resources. <a href="./references#CD012436-bbs2-0018" title="VanMilEG , WesterterpKR , KesterAD , Delemarre‐van de WaalHA , GerverWJ , SarisWH . The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology &amp; Metabolism2007;92(4):1409‐14. ">Van Mil 2007</a> measured total energy expenditure, using the Maastricht protocol and included data from a seven‐day dietary record; however, the difference between the sibutramine and control groups after 12 weeks of intervention was not statistically significant. Physical activity level was also measured using an activity questionnaire, but there was no statistically significant difference between groups at 12 weeks. Changes in total energy expenditure and physical activity levels were not measured at 24‐week follow‐up due to unavailability of equipment. </p> </section> <section id="CD012436-sec-0105"> <h6 class="title">Participants' views of the intervention</h6> <p>No trials investigated participants' views of the intervention.</p> </section> <section id="CD012436-sec-0106"> <h6 class="title">Morbidity</h6> <p>Only one trial investigated morbidity defined as illness or harm associated with the intervention (<a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>). In the orlistat group, 6/352 (1.7%) participants developed new gallstones compared with 1/181 (0.6%) in the placebo group. The certainty of the evidence was very low. </p> <p>Some trials investigated various risk indicators, mainly insulin resistance or insulin sensitivity and hyperinsulinaemia (<a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a>; <a href="./references#CD012436-bbs2-0005" title="ClarsonCL , MahmudFH , BakerJE , ClarkHE , MckayWM , SchauteetVD , et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine2009;36(1):141‐6. [DOI: 10.1007/s12020‐009‐9196‐9] ">Clarson 2009</a>; <a href="./references#CD012436-bbs2-0007" title="FreemarkM . Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. Acta Paediatrica2007;96:1326‐32. [DOI: 10.1111/j.1651‐2227.2007.00429.x] FreemarkM , BurseyD . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics2001;107(4):e55. ">Freemark 2001</a>; <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0017" title="SrinivasanS , AmblerGR , BaurLA , GarnettSP , TepsaM , YapF , et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2074‐80. [DOI: 10.1210/jc.2006‐0241] ">Srinivasan 2006</a>; <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>; <a href="./references#CD012436-bbs2-0021" title="AdeyemoMA , McDuffieJR , KozloskyM , KrakoffJ , CalisKA , BradySM , et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, Obesity and Metabolism2015;17(4):363‐70. [DOI: 10.1111/dom.12426] YanovskiJA , KrakoffJ , SalaitaCG , McDuffieJR , KozloskyM , SebringNG , et al. Effects of metformin on body weight and body composition in obese insulin‐resistant children a randomized clinical trial. Diabetes2011;60(2):477‐85. ">Yanovski 2011</a>). <a href="./references#CD012436-bbs2-0008" title="García‐MoralesLM , BerberA , Macias‐LaraCC , Lucio‐OrtizC , Del‐Rio‐NavarroBE , Dorantes‐AlvárezLM . Use of sibutramine in obese Mexican adolescents: a 6‐month, randomized, double‐blind, placebo‐controlled, parallel‐group trial. Clinical Therapeutics2006;28(5):770‐82. [DOI: 10.1016/j.clinthera.2006.05.008] ">García‐Morales 2006</a> investigated changes in blood pressure, glucose and triglycerides. <a href="./references#CD012436-bbs2-0015" title="PradoB , GaeteV , CoronaF , PeraltaE , DonosoP , RaimannX . Metabolic effects of metformin in obese adolescents at risk for type 2 diabetes mellitus [Efecto metabólico de la metformina en adolescentes obesas con riesgo de diabetes mellitus tipo 2]. Revista Chilena de Pediatría2012;83(1):48‐57. ">Prado 2012</a> investigated glycaemia, insulin resistance and lipid profiles. <a href="./references#CD012436-bbs2-0012" title="BensonM , HossainJ , CaulfieldMP , DamasoL , GiddingS , MaurasN . Lipoprotein subfractions by ion mobility in lean and obese children. Journal of Pediatrics2012;161:997‐1003. MaurasN , DelGiornoC , HossainJ , BirdK , KillenK , MerinbaumD , et al. Metformin use in children with obesity and normal glucose tolerance ‐ effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism2012;25(1‐2):33‐40. RyndersC , WeltmanA , DelgiornoC , BalagopalP , DamasoL , KillenK , et al. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Medicine &amp; Science in Sports &amp; Exercise2012;44(5):786‐92. [DOI: 10.1249/MSS.0b013e31823cef5e] ">Mauras 2012</a> investigated changes in hsCRP and fibrogen concentrations. </p> </section> <section id="CD012436-sec-0107"> <h6 class="title">All‐cause mortality</h6> <p>One trial reported a death from suicide (<a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>); the certainty of evidence was low. The authors reported that quality of life factors were screened extensively and the participant gave negative responses to quality of life questions specific to suicide and was also under the care of a psychiatrist for depression at the time of the trial. <a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a> reported two suicide attempts (one in the intervention group and one in the placebo group). </p> </section> <section id="CD012436-sec-0108"> <h6 class="title">Socioeconomic effects</h6> <p>No trials investigated socioeconomic effects.</p> <p>For a summary of all outcomes assessed in each trial, see <a href="./appendices#CD012436-sec-0129">Appendix 5</a>. For further explanation on how trial outcomes were defined, see <a href="./appendices#CD012436-sec-0131">Appendix 7</a> and <a href="./appendices#CD012436-sec-0132">Appendix 8</a>. </p> </section> </section> </section> <section id="CD012436-sec-0109"> <h4 class="title">Subgroup analyses</h4> <p>We performed subgroup analyses on our primary outcomes of BMI and weight. In our protocol, we specified we would analyse length of follow‐up; however, only two trials provided data at a time point greater than six months. There was too much heterogeneity to analyse the maintenance periods and most trials ended on completion of the intervention. In addition, there were only two trials which did not use a placebo; hence, we did not perform subgroup analyses based on type of control given. However, we performed subgroup analyses on BMI for the following factors: drug type (<a href="./references#CD012436-fig-0007" title="">Analysis 1.2</a>), dropout rates (<a href="./references#CD012436-fig-0008" title="">Analysis 1.3</a>), ITT analysis (<a href="./references#CD012436-fig-0009" title="">Analysis 1.4</a>), funding source (<a href="./references#CD012436-fig-0010" title="">Analysis 1.5</a>), publication date (<a href="./references#CD012436-fig-0011" title="">Analysis 1.6</a>), quality of trial (<a href="./references#CD012436-fig-0012" title="">Analysis 1.7</a>), country income (<a href="./references#CD012436-fig-0013" title="">Analysis 1.8</a>), and mean age of participants (<a href="./references#CD012436-fig-0014" title="">Analysis 1.9</a>). </p> <p>Only two interaction tests for subgroup differences indicated statistically significant differences. </p> <p>Comparing dropout rates less than 20% showed an MD in BMI change of ‐1.1 kg/m<sup>2</sup> (95% CI ‐1.8 to ‐0.4; 9 trials), with dropout rates 20% or greater showed an MD in BMI change of ‐1.4 kg/m<sup>2</sup> (95% CI ‐2.3 to ‐0.5; 6 trials), and with unclear dropout rates showed an MD in BMI change of ‐2.7 kg/m<sup>2</sup> (95% CI ‐3.7 to ‐1.7; 1 trial). The P value for interaction was 0.03 and heterogeneity was substantial (I<sup>2</sup> = 71%). </p> <p>Comparing middle‐income countries with high‐income countries showed an MD in BMI change of ‐2.4 kg/m<sup>2</sup> (95% CI ‐3.1 to ‐1.7; 3 trials) versus ‐1.1 kg/m<sup>2</sup> (95% CI ‐1.6 to ‐0.6; 13 trials). The P value for interaction was 0.004 and heterogeneity was considerable (I<sup>2</sup> = 88%). </p> <p>For the outcome measure change in weight, only drug type could be used for a subgroup analysis and the interaction test for subgroup differences was not statistically significant (P = 0.52, I<sup>2</sup> = 0%). </p> <p>We also explored the effects of participant sex on the BMI point estimate, using a meta‐regression model in CMA. The proportion of boys at follow‐up (or baseline if not reported) in each study was selected as a covariate. We found that the coefficient of determination (r<sup>2</sup>) from this model was zero. The 95% CI for the meta‐regression slope was extremely wide either side of zero (‐6.3 to 4.1). We noted that some study authors only reported the percentage of boys and girls in the total sample at baseline and not at follow‐up. </p> </section> <section id="CD012436-sec-0110"> <h4 class="title">Sensitivity analyses</h4> <p><a href="#CD012436-tbl-0003">Table 2</a> shows the sensitivity analyses on BMI change. Our first analysis removed the trials which only reported pre‐ and post‐BMI (not change scores) (<a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0019" title="HübelH . Prospective randomised controlled study for the prevention of type 2 diabetes mellitus in obese children and adolescents, 2012 [Prospektive, randomisierte, kontrollierte Studie zur Prävention des Typ 2 Diabetes mellitus bei adipösen Kindern und Jugendlichen (Dissertation)]. www.diss.fu‐berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000010572/2012.01.01.HHuebel.e_version_diss.pdf (last accessed 20 May 2016). WiegandS , l'AllemandD , HübelH , KrudeH , BürmannM , MartusP , et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin‐resistant adolescents: a prospective, placebo‐controlled, randomized study. European Journal of Endocrinology2010;163(4):585‐92. ">Wiegand 2010</a>), and hence required the use of a correlation coefficient of 0.78 (<a href="./references#CD012436-bbs2-0175" title="BayerO , KrügerH , KriesR , ToschkeAM . Factors associated with tracking of BMI: a meta‐regression analysis on BMI tracking. Obesity2011;19(5):1069‐76. ">Bayer 2011</a>) to predict the point estimates. This made very little difference in the point estimate. Only two trials had larger sample sizes (<a href="./references#CD012436-bbs2-0003" title="BerkowitzRI , FujiokaK , DanielsSR , HoppinAG , OwenS , PerryAC , et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of Internal Medicine2006;145(2):81‐90. DanielsSR , LongB , CrowS , StyneD , SothernM , Vargas‐RodriguezI , et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double‐blind, placebo‐controlled study. Pediatrics2007;120:e147‐57. [DOI: 10.1542/peds.2006‐2137] ">Berkowitz 2006</a>; <a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>); however, when we removed these trials from the meta‐analysis the point estimate did not change. Furthermore, all trials in the meta‐analysis were published and were in English; hence, we could not perform a sensitivity analysis on these criteria. However, we performed a sensitivity analysis with allocation bias, blinding bias (participant and trial personnel, and assessor) and attrition bias by removing the high risk or unclear risk trials, and did not find substantial differences. This was also the case when we removed trials with higher drug dose and 12 months' follow‐up, as well as when we removed the trials with an active lifestyle intervention. </p> <div class="table" id="CD012436-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sensitivity analyses: BMI</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Trials with data on mean change only</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Point estimate (95% CI) (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ 1.5 (‐2.0 to ‐0.9) favouring drug intervention</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Trials with concealment of allocation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Point estimate (95% CI) (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.3 (‐1.8 to ‐0.7) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Trials with blinding of participants/personnel</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Point estimate (95% CI) (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.3 (‐1.9 to ‐0.7) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Trials with blinding of outcome assessors</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Point estimate (95% CI) (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.3 (‐1.9 to ‐0.7) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Trials without large sample size trials</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Point estimate (95% CI) (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.3 (‐1.8 to ‐0.7) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Trials with trials with 6 months' follow‐up only</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Point estimate (95% CI) (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.2 (‐1.7 to ‐0.7) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Trials without trials with higher drug dose</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Point estimate (95% CI) (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.2 (‐1.7 to ‐0.7) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Trials with trials with a high dose/active lifestyle intervention</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Point estimate (95% CI) (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.3 (‐1.9 to ‐0.7) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Trials without trials with high attrition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Point estimate (95% CI) (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.4 (‐2.0 to ‐0.8) favouring drug interventions</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BMI: body mass index; CI: confidence interval.</p> </div> </div> <p>We performed similar analyses for weight change (<a href="#CD012436-tbl-0004">Table 3</a>). We removed trials which did not report change in weight (<a href="./references#CD012436-bbs2-0001" title="AtabekME , PirgonO . Use of metformin in obese adolescents with hyperinsulinemia: a 6‐month, randomized, double‐blind, placebo‐controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism2008;21(4):339‐48. ">Atabek 2008</a>; <a href="./references#CD012436-bbs2-0010" title="KendallD , VailA , AminR , BarrettT , DimitriP , IvisonF , et al. Metformin in obese children and adolescents: the MOCA trial. Journal of Clinical Endocrinology &amp; Metabolism2013;98(1):322‐9. [DOI: 10.1210/jc.2012‐2710] ">Kendall 2013</a>; <a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>), and this resulted in a slightly greater reduction in the point estimate. We used the same correlation coefficient to calculate the mean change in weight (in the intervention and comparator groups) as we did for the BMI outcome (r = 0.78), although we were able to calculate an exact correlation coefficient in one trial (<a href="./references#CD012436-bbs2-0011" title="MaahsD , deSernaDG , KolotkinRL , RalstonS , SandateJ , QuallsC , et al. Randomized, double‐blind, placebo‐controlled trial of orlistat for weight loss in adolescents. Endocrine Practice2006;12(1):18‐28. ">Maahs 2006</a>) by using their reported BMI at baseline, follow‐up and change score (r = 0.975). Reductions in point estimates increased slightly when we removed trials with blinding (participant and trial personnel, and assessor) and attrition bias. This also occurred when we restricted the analysis to trials which also included a high‐dose behaviour change intervention. In the sensitivity analyses where we removed trials with high allocation concealment bias, high drug dose, large sample size or follow‐up greater than six months, point estimate reductions were slightly less than in the original analysis. </p> <div class="table" id="CD012436-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Sensitivity analyses: weight</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Trials with data on mean change only</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Point estimate (95% CI) (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ 4.1 (‐6.3 to ‐1.8) favouring drug intervention</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Trials with concealment of allocation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Point estimate (95% CI) (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.5 (‐5.8 to ‐1.2) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Trials with blinding of participants/personnel</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Point estimate (95% CI) (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.2 (‐6.8 to ‐1.5) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Trials with blinding of outcome assessors</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Point estimate (95% CI) (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.2 (‐6.8 to ‐1.5) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Trials without large sample size trials</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Point estimate (95% CI) (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.4 (‐5.2 to ‐1.6) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Trials with 6 months' follow‐up only</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Point estimate (95% CI) (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.5 (‐5.6 to ‐1.4) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Trials without trials with higher drug dose</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Point estimate (95% CI) (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.4 (‐5.2 to ‐1.6) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Trials with trials with a high dose/active lifestyle intervention</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Point estimate (95% CI) (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.3 (‐6.5 to ‐2.2) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Trials without trials with high attrition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Point estimate (95% CI) (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.4 (‐6.6 to ‐2.2) favouring drug interventions</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval.</p> </div> </div> </section> <section id="CD012436-sec-0111"> <h4 class="title">Assessment of reporting bias</h4> <p>We drew a funnel plot in CMA version 3 and Review Manager 5 for change in BMI as there was a sufficient number of trials (16) (<a href="#CD012436-fig-0004">Figure 4</a>). The Egger's regression intercept was ‐0.75 (95% CI ‐3.2 to 1.7; P = 0.52); this suggests there was no evidence of reporting bias. </p> <div class="figure" id="CD012436-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Body mass index (BMI): pharmacological interventions versus comparators, outcome: 1.1 Change in BMI (all trials) (kg/m2)." data-id="CD012436-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Body mass index (BMI): pharmacological interventions versus comparators, outcome: 1.1 Change in BMI (all trials) (kg/m<sup>2</sup>). </p> </div> </div> </div> <p>There was a similar finding when we drew a funnel plot for change in weight (11 trials) (Egger's regression intercept 1.7, 95% CI ‐3.5 to 6.8; P = 0.48) (<a href="#CD012436-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD012436-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 Weight: pharmacological interventions versus comparators, outcome: 2.1 Change in weight (all trials) (kg)." data-id="CD012436-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Weight: pharmacological interventions versus comparators, outcome: 2.1 Change in weight (all trials) (kg). </p> </div> </div> </div> </section> <section id="CD012436-sec-0112"> <h4 class="title">Ongoing trials</h4> <p>We found eight ongoing RCTs with four receiving metformin in the intervention group (<a href="./references#CD012436-bbs2-0164" title="PastorMB , CaneteMD , HoyosR , LatorreM , Vazquez‐CobelaR , Rangel‐HuertaOD , et al. Metformin in the treatment of obese children shows differential response according to pubertal stage. Acta Physiologica. 2014; Vol. 212:36‐7. ">EUCTR2010‐023061‐21</a>; <a href="./references#CD012436-bbs2-0166" title="Effect of exercise or metformin on nocturnal blood pressure and other risk factors for CVD among obese adolescents. Ongoing studyTrial start date: February 2009Trial completion date: December 2012 (estimated). ">NCT00889876</a>; <a href="./references#CD012436-bbs2-0167" title="Obesity in children and adolescents: associated risks and early intervention (OCA). Ongoing studyTrial start date: May 2013Trial completion date: December 2015. ">NCT01677923</a>; <a href="./references#CD012436-bbs2-0170" title="Use of Metformin in Treatment of Childhood Obesity. Ongoing studyTrial start date: July 2014Trial completion date: February 2016. ">NCT02274948</a>), two receiving topiramate (<a href="./references#CD012436-bbs2-0168" title="Topiramate in Adolescents with Severe Obesity. Ongoing studyTrial start date: June 2013Trial completion date: December 2015. ">NCT01859013</a>; <a href="./references#CD012436-bbs2-0169" title="Topiramate and Severe Obesity (TOBI). Ongoing studyTrial start date: June 2015Trial completion date: December 2020. ">NCT02273804</a>), and two receiving exenatide (<a href="./references#CD012436-bbs2-0165" title="A study with lifestyle intervention and study medication once weekly or lifestyle intervention and placebo in adolescents with obesity to explore differences between groups with regard to change in BMI. Ongoing studyTrial start date: not givenTrial completion date: not given. ">EUCTR2015‐001628‐45‐SE</a>; <a href="./references#CD012436-bbs2-0171" title="Enhancing Weight Loss Maintenance With GLP‐1RA (BYDUREON™) in Adolescents with Severe Obesity. Ongoing studyTrial start date: December 2015Trial completion date: July 2020. ">NCT02496611</a>). Three trials, originally identified as ongoing, have been moved into the 'awaiting classification' section because the trial has been completed but no results are available on the clinical trial website or through a publication (<a href="./references#CD012436-bbs2-0158" title="">ISRCTN08063839</a>; <a href="./references#CD012436-bbs2-0160" title="ClarsonCL , BrownH , DejesusS , JackmanM , MahmudFH , PrapavessisH , et al. Structured lifestyle intervention with metformin extended release or placebo in obese adolescents. Diabetes. 2013; Vol. 62:A337‐8. WilsonAJ , PrapavessisH , JungME , CrampAG , VascottoJ , LenhardtL , et al. Lifestyle modification and metformin as long‐term treatment options for obese adolescents: study protocol. BMC Public Health2009;9:434. ">NCT00934570</a>; <a href="./references#CD012436-bbs2-0161" title="">NCT00940628</a>). In addition, one trial which was originally classified as ongoing was moved to the 'awaiting classification' section because during the final stages of conducting the review we identified a new publication (via the MEDLINE email alert service), which included results from 18‐month follow‐up (van der Aa 2016, see <a href="./references#CD012436-bbs2-0162" title="van derAaMP , ElstMA , vanMilEG , KnibbeCA , van derVorstMM . Metformin: an efficacy, safety and pharmacokinetic study on the short‐term and long‐term use in obese children and adolescents ‐ study protocol of a randomized controlled study. Trials2014;15:207. van derAaMP , ElstMA , van deGardeEM , vanMilEG , KnibbeCA , van derVorstMM . Long‐term treatment with metformin in obese, insulin‐resistant adolescents: results of a randomized double‐blinded placebo‐controlled trial. Nutrition &amp; Diabetes2016;6(8):e228. [DOI: 10.1038/nutd.2016.37] ">NCT01487993</a> for a summary of the results). Results from this trial will be incorporated in the next update of the review. For two trials, we were unable to locate the source (<a href="./references#CD012436-bbs2-0157" title="GolebiowskaM , Chlebna‐SokolD , KobierskaI , KonopinskaA , MalekM , MastalskaA , et al. Clinical evaluation of teronac (mazindol) in the treatment of obesity in children. Part II. Anorectic properties and side effects (author's translation). Przeglad Lekarski1981;38:355‐8. ">Golebiowska 1981</a>; <a href="./references#CD012436-bbs2-0159" title="LinquetteA , Fossati , P . Hunger control with benzphetamine hydrochloride in the treatment of obesity [Le contrôle de la faim par le chlorydrate de benzphétamine dans le traitement de l'obésité]. Lille Medical1971;16(Suppl 2):620‐4. ">Linquette 1971</a>). In addition, we identified one conference abstract (Pastor 2014a, see <a href="./references#CD012436-bbs2-0164" title="PastorMB , CaneteMD , HoyosR , LatorreM , Vazquez‐CobelaR , Rangel‐HuertaOD , et al. Metformin in the treatment of obese children shows differential response according to pubertal stage. Acta Physiologica. 2014; Vol. 212:36‐7. ">EUCTR2010‐023061‐21</a>) and one conference poster (<a href="./references#CD012436-bbs2-0163" title="SmetaninaN , SeibokaiteA , ValickasR , KuprionisG , GrigonieneJJ , RokaiteR , et.al . Metformin in combination with lifestyle changes effectively reduces BMI and waist circumference in overweight/obese children and adolescents. Hormone Research in Paediatrics2015;84:229. ">Smetanina 2015</a>). We attempted to contact both authors but only received a reply from <a href="./references#CD012436-bbs2-0163" title="SmetaninaN , SeibokaiteA , ValickasR , KuprionisG , GrigonieneJJ , RokaiteR , et.al . Metformin in combination with lifestyle changes effectively reduces BMI and waist circumference in overweight/obese children and adolescents. Hormone Research in Paediatrics2015;84:229. ">Smetanina 2015</a>, who confirmed the trial had been completed but these data were still being analysed. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012436-sec-0113" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012436-sec-0113">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012436-sec-0173">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012436-sec-0113"></div> <section id="CD012436-sec-0114"> <h3 class="title" id="CD012436-sec-0114">Summary of main results</h3> <p>We included 21 published RCTs and eight ongoing RCTs in this review. The included trials evaluated metformin (11 trials), sibutramine (six trials), orlistat (four trials), and one trial arm investigating the combination of metformin plus fluoxetine. The ongoing trials included four metformin, two topiramate and two exenatide trials. There were 2484 participants in the included trials, 1478 participants were randomised to drug intervention groups and 904 to comparator groups. All trials but three used a placebo in the comparator group. Two trials had a cross‐over design while the remaining 19 trials were parallel RCTs. The length of the intervention period ranged from 12 weeks to 48 weeks, and the length of follow‐up from baseline ranged from six months to 100 weeks. Overall there were small reductions in BMI (MD ‐1.3, 95% CI ‐1.9 to ‐0.8) and bodyweight change (MD ‐3.9 kg. 95% CI ‐5.9 to ‐1.9) in favour of the drug interventions. Five trials reported serious adverse events (24/878 (2.7%) participants in the intervention groups versus 8/469 (1.7%) participants in the comparator groups; RR 1.43, 95% CI 0.63 to 3.25; 1347 participants; low certainty evidence). A total of 52/1043 (5.0%) participants in the intervention groups versus 17/621 (2.7%) in the comparator groups discontinued the trial because of adverse events (RR 1.45, 95% CI 0.83 to 2.52; 10 trials; 1664 participants; low certainty evidence). The most common adverse events in orlistat and metformin trials were gastrointestinal. Common adverse effects in sibutramine trials included tachycardia, constipation and hypertension. The fluoxetine trial reported dry mouth and loose stools. One trials reported health‐related quality of life showing no marked differences between intervention and comparator. No trial reported the participants' views of the intervention or socioeconomic effects. Only one trial reported on morbidity associated with the intervention where there were more gallstones after the orlistat treatment. Trial authors reported one suicide in one of the orlistat intervention groups. However, the trials were not sufficiently long to investigate all‐cause mortality reliably. No trial investigated drug treatment for overweight children. </p> </section> <section id="CD012436-sec-0115"> <h3 class="title" id="CD012436-sec-0115">Overall completeness and applicability of evidence</h3> <p>We faced problems in meta‐analysing BMI as some trials did not report the raw data we required; therefore, we had to try and obtain this from the trial authors. In addition, age and sex are usually taken into account when measuring the weight status of a child because they are growing. However, in this review, we only assessed changes in raw BMI because previous research has shown short‐term changes in adiposity are best represented by changes in raw BMI units compared to BMI z scores or BMI centiles (<a href="./references#CD012436-bbs2-0187" title="ColeTJ , FaithMS , PietrobelliA , HeoM . What is the best measure of adiposity change in growing children: BMI, BMI %, BMI z‐score or BMI centile?. European Journal of Clinical Nutrition2005;59:419‐25. ">Cole 2005</a>; <a href="./references#CD012436-bbs2-0218" title="KakinamiL , HendersonM , ChioleroA , ColeTJ , ParadisG . Identifying the best body mass index metric to assess adiposity change in children. Archives of Disease in Childhood2014;99:1020‐4. ">Kakinami 2014</a>). Furthermore, only 10 trials reported changes in BMI z scores; therefore, we thought it was more appropriate to only meta‐analyse raw BMI, then this change could be converted into change in BMI z score (using the desired growth reference) ‐ which we have done in the conclusion section of this review. </p> <p>All 21 trials measured adverse events; however, some trials reported the total number of participants who experienced at least one adverse event whilst others only reported the number of specific adverse events. Hence, we also had to attempt to obtain this information from the trial authors. Of the six trials which measured behaviour change, only two trials reported the results at follow‐up. Only two trials reported health‐related quality of life and they used different methods. Hence, more trials are needed to investigate how drugs used to treat obesity affect the participants' health‐related quality of life. No trials reported differences in participant views or socioeconomic effects. </p> </section> <section id="CD012436-sec-0116"> <h3 class="title" id="CD012436-sec-0116">Quality of the evidence</h3> <p>Based on the GRADE criteria, we rated the outcomes BMI, body weight, all‐cause mortality and adverse events as low. We downgraded the levels of evidence because of potential other risk of bias or reporting bias, inconsistency and imprecision. We rated health‐related quality of life and morbidity as very low certainty evidence, mainly because of the small number of participants, one trial only and imprecision. </p> </section> <section id="CD012436-sec-0117"> <h3 class="title" id="CD012436-sec-0117">Potential biases in the review process</h3> <p>We decided to perform unplanned subgroup analyses looking at funding and country as there were enough trials to divide them into groups. We were unable to analyse length of follow‐up, impact of maintenance periods and type of control group in the subgroup analyses as there were too few trials or too much heterogeneity. The meta‐analyses for BMI and weight included trials which differed in follow‐up length, behavioural interventions and drug dose. However, when sensitivity analyses were performed, the changes in point estimates were small. </p> <p>We did not restrict our search strategy to any date, hence we have sifted through trials ranging back to the 1960s. However, we did not undertake any searches of the grey literature. We had some correspondence with most of trial authors, and some have supplied us with additional information including raw BMI data. Only seven trials gave clinical trial identifiers or protocols available; hence, it was difficult to assess whether reporting bias occurred. However, from the trials where a protocol/clinical trial entry was available, there was little evidence to suggest a source of reporting bias. We excluded a large number of trials because of follow‐up times less than six months, especially older trials, and this may have impacted on the overall findings from this review. In addition, we had difficulties calculating the number of adverse events in each trial due to different reporting metrics; for example, some trials reported the total number of adverse events in each group whilst others reported the total number of participants who suffered at least one adverse event. Despite our attempts to contact authors for additional information, we were still unable to meta‐analyse most of these findings. </p> </section> <section id="CD012436-sec-0118"> <h3 class="title" id="CD012436-sec-0118">Agreements and disagreements with other studies or reviews</h3> <p>Since the previous review (<a href="./references#CD012436-bbs2-0279" title="Oude LuttikhuisH , BaurL , JansenH , ShrewsburyVA , O'MalleyC , StolkRP , et al. Interventions for treating obesity in children. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD001872.pub2] ">Oude Luttikhuis 2009</a>), we identified one new orlistat trial; however, the reduction in BMI was similar to what was found previously. The reduction in BMI for the sibutramine trials found in this review was smaller than the change reported in the previous review; however, these data still favour the intervention. This difference is likely to be due to the inclusion of three extra sibutramine trials in the meta‐analysis. The previous review did not include a meta‐analysis of metformin trials. </p> <p>Another review and meta‐analysis of the effect of orlistat and sibutramine on adolescent weight loss derived a difference in BMI of ‐2.3 kg/m<sup>2</sup> for sibutramine (95% CI ‐2.9 to ‐1.8; 5 trials; 770 participants) and ‐1.7 kg/m<sup>2</sup> for orlistat (95% CI ‐3.5 to 0.2; 3 trials; 621 participants) (<a href="./references#CD012436-bbs2-0190" title="CzernichowS , LeeCM , BarziF , GreenF . Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: a meta‐analysis of randomized controlled trials. Obesity Reviews2010;11(2):150‐8. ">Czernichow 2010</a>). These point estimates reductions are greater than the ones derived in our review. However, the orlistat point estimate in the <a href="./references#CD012436-bbs2-0190" title="CzernichowS , LeeCM , BarziF , GreenF . Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: a meta‐analysis of randomized controlled trials. Obesity Reviews2010;11(2):150‐8. ">Czernichow 2010</a> review includes the <a href="./references#CD012436-bbs2-0014" title="OzkanB , BereketA , TuranS , KeskinS . Addition of orlistat to conventional treatment in adolescents with severe obesity. European Journal of Pediatrics2004;163(12):738‐41. ">Ozkan 2004</a> trial with a large BMI weight reduction which we excluded from the meta‐analysis in our review for not having a common follow‐up time across participants. In addition, the sibutramine analysis included data from a secondary analysis of white and African‐American participants from <a href="./references#CD012436-bbs2-0002" title="BerkowitzRI , WaddenTA , TershakovecAM , CronquistJL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA2003;289(14):1805‐12. Bishop‐GilyardCT , BerkowitzRI , WaddenTA , GehrmanCA , CronquistJL , MooreRH . Weight reduction in obese adolescents with and without binge eating. Obesity (Silver Spring)2011;19(5):982‐7. BuddGM , HaymanLL , CrumpE , PollydoreC , HawleyK , CronquistJL , et al. Weight loss in obese African American and Caucasian adolescents. Journal of Cardiovascular Nursing2007;22(4):288‐96. ParksEP , ZemelB , MooreRH , BerkowitzRI . Change in body composition during a weight loss trial in obese adolescents. Pediatric Obesity2014;9:26‐35. ">Berkowitz 2003</a> which may explain why the point estimate was different. In an earlier review, there was an MD of ‐0.7 kg/m<sup>2</sup> (95% CI ‐1.2 to ‐0.3) in orlistat participants compared to placebo, which is consistent with our findings (<a href="./references#CD012436-bbs2-0234" title="McGovernL , JohnsonJN , PauloR , HettingerA , SinghalV , KamathC , et al. Treatment of pediatric obesity: a systematic review and meta‐analysis of randomized trials. Journal of Clinical Endocrinology and Metabolism2008;93(12):4600‐5. ">McGovern 2008</a>). There was a reduction of ‐2.4 kg/m<sup>2</sup> (95% CI ‐3.1 to ‐1.8) in sibutramine trials, which is higher than the reduction we found (<a href="./references#CD012436-bbs2-0234" title="McGovernL , JohnsonJN , PauloR , HettingerA , SinghalV , KamathC , et al. Treatment of pediatric obesity: a systematic review and meta‐analysis of randomized trials. Journal of Clinical Endocrinology and Metabolism2008;93(12):4600‐5. ">McGovern 2008</a>). There were similar findings also found in another meta‐analysis where the reduction for sibutramine was an MD of ‐2.2 kg/m<sup>2</sup> (95% CI ‐2.8 to ‐1.6; 4 trials; 686 participants) and the reduction for orlistat was an MD of ‐0.8 (95% CI ‐1.2 to ‐0.5; 2 trials; 573 participants) (<a href="./references#CD012436-bbs2-0264" title="VinerRM , HsiaY , TomsicT , WongIC . Efficacy and safety of anti‐obesity drugs in children and adolescents: systematic review and meta‐analysis. Obesity Reviews2010;11(8):593‐602. ">Viner 2010</a>). </p> <p>In metformin trials, <a href="./references#CD012436-bbs2-0233" title="McDonaghM , SelphS , OzpinarA , FoleyC . Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. JAMA Pediatrics2014;168(2):178‐84. [DOI: 10.1001/jamapediatrics.2013.4200] ">McDonagh 2014</a> determined an effect size of an MD of ‐1.2 kg/m<sup>2</sup> (95% CI ‐1.6 to ‐0.7; 13 trials), which is similar to the point estimate found in this review. In addition, <a href="./references#CD012436-bbs2-0180" title="BouzaC , Lopez‐CuadradoT , Gutierrez‐TorresLF , AmateJ . Efficacy and safety of metformin for treatment of overweight and obesity in adolescents: an updated systematic review and meta‐analysis. Obesity Facts2012;5:753‐65. ">Bouza 2012</a> found a reduction of a MD of ‐1.2 kg/m<sup>2</sup> (95% CI ‐1.8 to ‐0.5; 7 trials), in favour of metformin. An earlier review found a reduction of ‐1.4 kg/m<sup>2</sup> (95% CI ‐2 to ‐0.8; 5 trials; 320 participants) in metformin trials (<a href="./references#CD012436-bbs2-0242" title="ParkMH , KinraS , WardKJ , WhiteB , VinerRM . Metformin for obesity in children and adolescents: a systematic review. Diabetes Care2009;32(9):1743‐5. ">Park 2009</a>); however, the review only included five trials and we excluded one of the trials in this review (<a href="./references#CD012436-bbs2-0093" title="Love‐OsborneK , SheederJ , ZeitlerP . Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. Journal of Pediatrics2008;152:817‐22. ">Love‐Osborne 2008</a>). </p> <p>Overall findings from meta‐analyses of metformin, sibutramine and orlistat trials are similar to the ones presented in this review, and reasons for any differences are likely to derive from different inclusion criteria and our inclusion of more recent trials. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012436-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/urn:x-wiley:14651858:media:CD012436:CD012436-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_t/tCD012436-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Trial flow diagram." data-id="CD012436-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Trial flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012436/full#CD012436-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012436-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/urn:x-wiley:14651858:media:CD012436:CD012436-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_t/tCD012436-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials." data-id="CD012436-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012436/full#CD012436-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012436-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/urn:x-wiley:14651858:media:CD012436:CD012436-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_t/tCD012436-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial." data-id="CD012436-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012436/full#CD012436-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012436-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/urn:x-wiley:14651858:media:CD012436:CD012436-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_t/tCD012436-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Body mass index (BMI): pharmacological interventions versus comparators, outcome: 1.1 Change in BMI (all trials) (kg/m2)." data-id="CD012436-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Body mass index (BMI): pharmacological interventions versus comparators, outcome: 1.1 Change in BMI (all trials) (kg/m<sup>2</sup>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012436/full#CD012436-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012436-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/urn:x-wiley:14651858:media:CD012436:CD012436-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_t/tCD012436-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 Weight: pharmacological interventions versus comparators, outcome: 2.1 Change in weight (all trials) (kg)." data-id="CD012436-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Weight: pharmacological interventions versus comparators, outcome: 2.1 Change in weight (all trials) (kg). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012436/full#CD012436-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012436-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/urn:x-wiley:14651858:media:CD012436:CD012436-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_t/tCD012436-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators, Outcome 1 Change in BMI (all trials)." data-id="CD012436-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators, Outcome 1 Change in BMI (all trials). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012436/references#CD012436-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012436-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/urn:x-wiley:14651858:media:CD012436:CD012436-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_t/tCD012436-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators, Outcome 2 Change in BMI (drug type)." data-id="CD012436-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators, Outcome 2 Change in BMI (drug type). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012436/references#CD012436-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012436-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/urn:x-wiley:14651858:media:CD012436:CD012436-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_t/tCD012436-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators, Outcome 3 Change in BMI (dropout rate)." data-id="CD012436-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators, Outcome 3 Change in BMI (dropout rate). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012436/references#CD012436-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012436-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/urn:x-wiley:14651858:media:CD012436:CD012436-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_t/tCD012436-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators, Outcome 4 Change in BMI (intention‐to‐treat (ITT) analysis)." data-id="CD012436-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators, Outcome 4 Change in BMI (intention‐to‐treat (ITT) analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012436/references#CD012436-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012436-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/urn:x-wiley:14651858:media:CD012436:CD012436-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_t/tCD012436-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators, Outcome 5 Change in BMI (funding)." data-id="CD012436-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators, Outcome 5 Change in BMI (funding). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012436/references#CD012436-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012436-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/urn:x-wiley:14651858:media:CD012436:CD012436-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_t/tCD012436-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators, Outcome 6 Change in BMI (publication date)." data-id="CD012436-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators, Outcome 6 Change in BMI (publication date). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012436/references#CD012436-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012436-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/urn:x-wiley:14651858:media:CD012436:CD012436-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_t/tCD012436-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators, Outcome 7 Change in BMI (quality of trial)." data-id="CD012436-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators, Outcome 7 Change in BMI (quality of trial). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012436/references#CD012436-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012436-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/urn:x-wiley:14651858:media:CD012436:CD012436-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_t/tCD012436-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators, Outcome 8 Change in BMI (country)." data-id="CD012436-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators, Outcome 8 Change in BMI (country). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012436/references#CD012436-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012436-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/urn:x-wiley:14651858:media:CD012436:CD012436-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_t/tCD012436-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators, Outcome 9 Change in BMI (mean age)." data-id="CD012436-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators, Outcome 9 Change in BMI (mean age). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012436/references#CD012436-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012436-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/urn:x-wiley:14651858:media:CD012436:CD012436-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_t/tCD012436-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Weight: pharmacological interventions versus comparators, Outcome 1 Change in weight (all trials)." data-id="CD012436-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Weight: pharmacological interventions versus comparators, Outcome 1 Change in weight (all trials). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012436/references#CD012436-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012436-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/urn:x-wiley:14651858:media:CD012436:CD012436-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_t/tCD012436-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Weight: pharmacological interventions versus comparators, Outcome 2 Change in weight (drug type)." data-id="CD012436-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Weight: pharmacological interventions versus comparators, Outcome 2 Change in weight (drug type). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012436/references#CD012436-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012436-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/urn:x-wiley:14651858:media:CD012436:CD012436-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_t/tCD012436-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adverse effects: pharmacological interventions versus comparator, Outcome 1 Serious adverse events." data-id="CD012436-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Adverse effects: pharmacological interventions versus comparator, Outcome 1 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012436/references#CD012436-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012436-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/urn:x-wiley:14651858:media:CD012436:CD012436-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_t/tCD012436-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adverse effects: pharmacological interventions versus comparator, Outcome 2 Discontinued trial because of adverse events." data-id="CD012436-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Adverse effects: pharmacological interventions versus comparator, Outcome 2 Discontinued trial because of adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012436/references#CD012436-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012436/media/CDSR/CD012436/image_n/nCD012436-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012436-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Drug interventions for the treatment of obesity in children and adolescents</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Drug interventions for the treatment of obesity in children and adolescents</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> obese children and adolescents </p> <p><b>Settings:</b> mainly outpatient settings </p> <p><b>Intervention:</b> metformin, orlistat, sibutramine usually combined with behaviour changing interventions </p> <p><b>Comparison:</b> placebo or no placebo usually with behaviour changing interventions </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Pharmacological intervention</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>a. BMI (</b>kg/m<sup>2</sup>)<br/> Follow‐up: 6 months (14 trials) ‐ 12 months (2 trials) </p> <p><b>b. Body weight (kg)</b> </p> <p>Follow‐up: 6 months (10 trials) ‐ 12 months (1 trial)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>a. The mean reduction in BMI ranged across control groups from ‐1.8 to +0.9</p> <p>b. The mean reduction in weight ranged across control groups from ‐3.8 kg to +4.9 kg </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>a. The mean reduction in BMI in the intervention groups was ‐<b>1.3 higher</b> (‐1.9 to ‐0.8 higher) </p> <p>b. The mean reduction in weight in the intervention groups was <b>‐3.9 kg higher</b> (‐5.9 kg to ‐1.9 kg higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 1884 (16)</p> <p>b. 1180 (11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a.</p> <p>⊕⊕⊝⊝<br/> <b>L ow<sup>a</sup> </b> </p> <p>b.</p> <p>⊕⊕⊝⊝<br/> <b>Low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>a. Serious adverse events</p> <p>b. Discontinuation of trial because of adverse events</p> <p>Follow‐up: mostly 6 months, maximum 100 weeks (1 trial)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>a. <b>17 per 1000</b> </p> <p>b. <b>27 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>a. <b>24 per 1000</b> (11 to 55) </p> <p>b. <b>40 per 1000</b> (23 to 69) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a.<b>RR 1.43</b> (0.63 to 3.25) </p> <p>b.<b>RR 1.45</b> (0.83 to 2.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. 1347 (5)</p> <p>b. 1664 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a.</p> <p>⊕⊕⊕⊝</p> <p><b>L ow<sup>b</sup> </b> </p> <p>b.</p> <p>⊕⊕⊕⊝</p> <p><b>Low<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All trials reported if adverse events occurred; however, only 7/20 trials reported the number of participants who experienced at least 1 adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> <p>3 questionnaires (1 trial) and SF‐36 (1 trial)</p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>V ery low<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results were only reported for SF‐36 (1 trial on sibutramine, 46 children), there were no marked differences between intervention and comparator groups </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: mostly 6 months, maximum 100 weeks (1 trial)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2176 (20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>L ow<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 suicide in the orlistat intervention group</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Morbidity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>533 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>V ery low<sup>e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 1 trial investigated morbidity defined as illness or harm associated with the intervention (<a href="./references#CD012436-bbs2-0004" title="ChanoineJ , HamplS , JensenC , BoldrinM , HauptmanJ . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA2005;293(23):2873‐83. ChanoineJP , RichardM . Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. International Journal of Pediatric Obesity2010;6(2):95‐101. [DOI: 10.3109/17477166.2010.519387] ">Chanoine 2005</a>). In the orlistat group 6/352 (1.7%) participants developed new gallstones compared with 1/181 (0.6%) in the placebo group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Socioeconomic effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>BMI:</b> body mass index; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SF‐36:</b> Short‐Form Health Survey 36 items. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*Assumed risk was derived from the event rates in the comparator groups.</p> <p><sup>a</sup>Downgraded by two levels because of potential other risk of bias, inconsistency and imprecision (see <a href="./appendices#CD012436-sec-0137">Appendix 13</a>).<br/> <sup>b</sup>Downgraded by two levels because of potential reporting bias, inconsistency and imprecision (see <a href="./appendices#CD012436-sec-0137">Appendix 13</a>).<br/> <sup>c</sup>Downgraded by three levels because of one trial only with a small number of participants and imprecision (see <a href="./appendices#CD012436-sec-0137">Appendix 13</a>).<br/> <sup>d</sup>Downgraded by two levels because of short follow‐up periods and no trial was powered to investigate mortality (see <a href="./appendices#CD012436-sec-0137">Appendix 13</a>).<br/> <sup>e</sup>Downgraded by three levels because of one trial only and imprecision (see <a href="./appendices#CD012436-sec-0137">Appendix 13</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Drug interventions for the treatment of obesity in children and adolescents</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012436/full#CD012436-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012436-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of trial populations</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Description of power and sample size calculation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Screened/eligible<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Safety<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ITT<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Finishing trial<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised finishing trial<br/> (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up time<sup>a</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Atabek 2008<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin + diet and physical activity advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + diet and physical activity advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Berkowitz 2003</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: behavioural programme + sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Powered to detect a 4% difference in % change in BMI between the 2 treatment groups with an SD of 5% (α = 0.05, β = 93%)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months (not including the 6‐month open‐label period where all participants received sibutramine) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: behavioural programme + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.2</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Berkowitz 2006</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: behavioural programme + sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Planned sample size was approximately 400 participants with a 3:1 randomization ratio of sibutramine to placebo. On the basis of previous 12‐month adult trials, we determined that 300 participants in the sibutramine group would be adequate to assess safety and exposure, allowing an overall dropout rate of approximately 50% and a probability that approximately 50% of participants receiving 10 mg of sibutramine would lose 10% or more of initial BMI at 6 months" </p> <p>"Although the protocol did not document a formal sample size calculation for efficacy, approximately 132 adolescents (99 in the sibutramine group and 33 in the placebo group) would allow a between‐group difference in BMI of 2 kg/m<sup>2</sup>, with 90% power (2‐sided level of 0.05) to be statistically significant, assuming a common SD of 3 kg/m<sup>2</sup>)"<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: behavioural programme + placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.5</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Chanoine 2005</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: orlistat + diet + exercise + behaviour therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"We planned to enroll at least 450 individuals to provide more than 80% power to detect a difference of 1 BMI unit, assuming a 30% dropout rate" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>54 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + diet + exercise + behaviour therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.3</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>539</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>533</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Clarson 2009</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin + lifestyle intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: lifestyle intervention only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.4</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Franco 2014</b> </p> <p><b>(cross‐over trial)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: sibutramine + dietary guidance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>13 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + dietary guidance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>‐</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Freemark 2001</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.2</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Garcia‐Morales 2006</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: sibutramine + diet + exercise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13 participants per group (expectations: mean loss of 7.5 kg (SD 5.3) in the sibutramine group vs 3.6 kg (SD 4.5) in the placebo group)<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + diet + exercise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.0</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Godoy‐Matos 2005</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: sibutramine + hypocaloric diet + exercise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>24 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + hypocaloric diet + exercise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.3</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Kendall 2013</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin + healthy lifestyle advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"The target recruitment was 140 patients, based on a power calculation using the results of a previous study. A standard power calculation was used to detect a reduction in BMI of 0.15 kg/m<sup>2</sup> (SD 0.3). Sixty‐four participants in each group give a statistical power of 80% for a t test at the 5% significance level. This was rounded up to allow for some loss to follow‐up but recognizing that adjustment using multifactorial analysis would likely enhance the trial power by an unpredictable amount"<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + healthy lifestyle advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Maahs 2006</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: orlistat + diet and exercise therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"We determined that a clinically important mean difference in decrease in BMI between the orlistat and placebo groups would be 2.0 kg/m<sup>2</sup> at 6 months and used an SD of 1.8. On the basis of this approach, a sample size of 15 subjects per group would be adequate to detect a 2.0 kg/m<sup>2</sup> difference in Student’s t test with 80% power and alpha = 0.05. In order to allow for a 25% dropout rate, 20 subjects were randomized to each group"<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + diet and exercise therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.0</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Mauras 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin + diet/exercise intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Differences in hsCRP and fibrinogen concentrations at 6 months were the primary outcomes. An n = 42 completed subjects provided &gt; 90 % power to detect significant changes" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: diet/exercise intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.3</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>NCT00001723</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: orlistat + behavioural weight loss programme</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + behavioural weight loss programme</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Ozkan 2004</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: conventional treatment (nutritional and lifestyle modification programmes) + orlistat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>5 to 15 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: conventional treatment: nutritional and lifestyle modification programmes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.0</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Prado 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin + nutritional guide and exercise programme</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 participants were required per intervention group (SD 0.4; difference of 0.6, P &lt; 0.05, power = 90%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>41/26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + nutritional guide and exercise programme</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><b>Rezvanian 2010</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: metformin + diet and physical activity advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>"By considering alpha = 0.05 and a power level of 0.8, the sample size was calculated as 160, and by considering the attrition during the follow‐up, we increased it to 180" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>24 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: fluoxetine + diet and physical activity advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I3: metformin and fluoxetine + diet and physical activity advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + diet and physical activity advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.3</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Srinivasan 2006</b> </p> <p><b>(cross‐over trial)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin + "standardised information on healthy eating and exercise"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>‐</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + "standardised information on healthy eating and exercise"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>‐</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Van Mil 2007</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: sibutramine + energy‐restricted diet and exercise plan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"The number of patients required per treatment group to detect a difference between treatment groups in mean change in BMI at endpoint intervention of 1.0 kg/m<sup>2</sup>, based on an estimate of variance (sd) of 0.65, an overall significance level of 5%, and a power of 90%, was nine. Allowing a drop‐out rate of 25%, the number of patients needed in each group was 12"<sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>24 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + energy‐restricted diet and exercise plan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.0</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Wiegand 2010</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin + lifestyle intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Since a clinically significant effect was defined as a decrease in HOMA‐IR by ‐1, two groups of 37 patients had to be included in the study to achieve a power of 0.9 with a α value of 0.05" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + lifestyle intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.3</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Wilson 2010</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin + lifestyle intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Assuming an SD of 1.9 for BMI change, an enrolled sample of 72 provided 80% power to detect a differential of 1.46 between treatment arms or between sexes and 1.75 between white subjects and others"<sup>i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>100 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + lifestyle intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.0</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Yanovski 2011</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: metformin + dietitian‐administered weight‐reduction programme</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"A total sample size of 60 participants would detect a between‐group difference of 0.09 BMI SD score units (approximately equivalent to a 2 kg/m<sup>2</sup> difference) with 80% power. Participant accrual was set at 100 participants to allow as much as 40% loss to follow‐up"<sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months (not including the 6‐month open‐label phase)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo + dietitian‐administered weight‐reduction programme</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.1</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b><i>Grand total</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>All interventions<sup>k</sup> </i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>1395</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>1153</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>All comparators<sup>k</sup> </i> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>817</i> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>665</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>All interventions and comparators<sup>k</sup> </i> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>2484</i> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>1851</i> </b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><sup>a</sup>Duration of intervention and follow‐up under randomised conditions until end of trial.<br/> <sup>b</sup>Unclear from the publication on the number which completed the trial and hence number of dropouts.<br/> <sup>c</sup>Actual treatment difference between intervention groups was 4.5% reduction in BMI.<br/> <sup>d</sup>Actual treatment difference between intervention groups at 12 months was 2.9 kg/m<sup>2</sup>.<br/> <sup>e</sup>Actual weight loss was 7.3 kg in the sibutramine group vs 4.3 kg in the placebo group.<br/> <sup>f</sup>Actual adjusted treatment difference at 6 months was ‐1.07 kg/m<sup>2</sup>.<br/> <sup>g</sup>Actual treatment difference between intervention groups at 6 months was 0.5 kg/m<sup>2</sup>.<br/> <sup>h</sup>Actual treatment difference between intervention groups at end of intervention (12 weeks) was 0.4 kg/m<sup>2</sup> and at end of follow‐up (24 weeks) was 1.0 kg/m<sup>2</sup>.<br/> <sup>i</sup>Actual treatment difference between intervention groups after 48 weeks was 1.1 kg/m<sup>2</sup>.<br/> <sup>j</sup>Actual treatment difference between intervention groups at 6 months for BMI z score was 0.07.<br/> <sup>k</sup>Numbers for interventions and comparators do not add up to 'all interventions and comparators' because several trials did not provide information on randomised participants per intervention/comparator group but only the total number of randomised participants. </p> <p>"‐" denotes not reported.</p> <p>BMI: body mass index; C: comparator; hsCRP: high sensitivity C‐reactive protein; HOMA‐IR: homeostasis model assessment for insulin resistance index; I: intervention; ITT: intention‐to‐treat; n: number of participants; SD: standard deviation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of trial populations</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012436/full#CD012436-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012436-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sensitivity analyses: BMI</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Trials with data on mean change only</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Point estimate (95% CI) (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ 1.5 (‐2.0 to ‐0.9) favouring drug intervention</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Trials with concealment of allocation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Point estimate (95% CI) (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.3 (‐1.8 to ‐0.7) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Trials with blinding of participants/personnel</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Point estimate (95% CI) (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.3 (‐1.9 to ‐0.7) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Trials with blinding of outcome assessors</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Point estimate (95% CI) (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.3 (‐1.9 to ‐0.7) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Trials without large sample size trials</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Point estimate (95% CI) (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.3 (‐1.8 to ‐0.7) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Trials with trials with 6 months' follow‐up only</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Point estimate (95% CI) (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.2 (‐1.7 to ‐0.7) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Trials without trials with higher drug dose</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Point estimate (95% CI) (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.2 (‐1.7 to ‐0.7) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Trials with trials with a high dose/active lifestyle intervention</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Point estimate (95% CI) (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.3 (‐1.9 to ‐0.7) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Trials without trials with high attrition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Point estimate (95% CI) (kg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.4 (‐2.0 to ‐0.8) favouring drug interventions</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>BMI: body mass index; CI: confidence interval.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sensitivity analyses: BMI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012436/full#CD012436-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012436-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Sensitivity analyses: weight</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Trials with data on mean change only</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Point estimate (95% CI) (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ 4.1 (‐6.3 to ‐1.8) favouring drug intervention</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Trials with concealment of allocation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Point estimate (95% CI) (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.5 (‐5.8 to ‐1.2) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Trials with blinding of participants/personnel</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Point estimate (95% CI) (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.2 (‐6.8 to ‐1.5) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Trials with blinding of outcome assessors</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Point estimate (95% CI) (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.2 (‐6.8 to ‐1.5) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Trials without large sample size trials</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Point estimate (95% CI) (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.4 (‐5.2 to ‐1.6) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Trials with 6 months' follow‐up only</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Point estimate (95% CI) (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.5 (‐5.6 to ‐1.4) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Trials without trials with higher drug dose</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Point estimate (95% CI) (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.4 (‐5.2 to ‐1.6) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Trials with trials with a high dose/active lifestyle intervention</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Point estimate (95% CI) (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.3 (‐6.5 to ‐2.2) favouring drug interventions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Trials without trials with high attrition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Point estimate (95% CI) (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.4 (‐6.6 to ‐2.2) favouring drug interventions</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>CI: confidence interval.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Sensitivity analyses: weight</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012436/full#CD012436-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012436-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Body mass index (BMI): pharmacological interventions versus comparators</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in BMI (all trials) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1884</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.34 [‐1.85, ‐0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Change in BMI (drug type) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1884</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.34 [‐1.85, ‐0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.35 [0.00, ‐0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Orlistat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.79 [‐1.08, ‐0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐2.89, ‐0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Change in BMI (dropout rate) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1862</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.34 [‐1.85, ‐0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Dropouts &lt; 20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.11 [‐1.78, ‐0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Dropouts ≥ 20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.42 [‐2.34, ‐0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Unclear dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.73 [‐3.74, ‐1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Change in BMI (intention‐to‐treat (ITT) analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1862</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.34 [‐1.85, ‐0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 No ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.56 [‐2.52, ‐0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 ITT used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1580</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.25 [‐1.86, ‐0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Change in BMI (funding) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1862</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.34 [‐1.85, ‐0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Commercial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐2.69, ‐0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Noncommercial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.10 [‐1.77, ‐0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Commercial + noncommercial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.17 [‐1.86, ‐0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.79 [‐3.54, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Change in BMI (publication date) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1862</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.34 [‐1.85, ‐0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 2007 or before</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.41 [‐2.21, ‐0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 After 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>699</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.26 [‐1.90, ‐0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Change in BMI (quality of trial) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1862</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.34 [‐1.85, ‐0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.40 [‐2.28, ‐0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1540</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.31 [‐1.95, ‐0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Change in BMI (country) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1862</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.34 [‐1.85, ‐0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Middle income</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.39 [‐3.08, ‐1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 High income</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.09 [‐1.62, ‐0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Change in BMI (mean age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1884</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.34 [‐1.85, ‐0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Mean age &lt; 12 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.93 [‐3.53, ‐0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Mean age ≥ 12 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.25 [‐1.79, ‐0.71]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Body mass index (BMI): pharmacological interventions versus comparators</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012436/references#CD012436-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012436-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Weight: pharmacological interventions versus comparators</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in weight (all trials) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.90 [‐5.86, ‐1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Change in weight (drug type) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.90 [‐5.86, ‐1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.24 [‐5.79, ‐0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.71 [‐8.10, ‐1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Orlistat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.48 [‐4.31, ‐0.65]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Weight: pharmacological interventions versus comparators</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012436/references#CD012436-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012436-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Adverse effects: pharmacological interventions versus comparator</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.63, 3.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.25, 100.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Orlistat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.41, 2.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.53 [0.46, 27.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Discontinued trial because of adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.83, 2.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.26, 5.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Orlistat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>815</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.49 [0.74, 8.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Sibutramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.53, 2.46]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Adverse effects: pharmacological interventions versus comparator</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012436/references#CD012436-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012436&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012436-note-0002">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012436-note-0009">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012436-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012436-note-0007">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012436-note-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD012436-note-0021">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012436-note-0006">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD012436-note-0004">Русский</a> </li> <li class="section-language"> <a class="" href="ta#CD012436-note-0008">தமிழ்</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012436-note-0003">繁體中文</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012436-note-0010">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012436\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012436\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012436\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012436"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012436\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012436\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012436\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012436\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012436\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012436"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012436\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012436\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012436\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012436"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012436\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012436\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012436\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012436"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XHP2gG4h&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012436&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012436';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012436/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012436/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012436%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719127757"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012436/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719127761"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012436/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de1261d611be4',t:'MTc0MDcxOTEyOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 